US20080026108A1 - Encapsulated Labile Compound Compositions and Methods of Making the Same - Google Patents
Encapsulated Labile Compound Compositions and Methods of Making the Same Download PDFInfo
- Publication number
- US20080026108A1 US20080026108A1 US11/767,366 US76736607A US2008026108A1 US 20080026108 A1 US20080026108 A1 US 20080026108A1 US 76736607 A US76736607 A US 76736607A US 2008026108 A1 US2008026108 A1 US 2008026108A1
- Authority
- US
- United States
- Prior art keywords
- product
- encapsulant
- group
- acid
- labile compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 118
- 238000000034 method Methods 0.000 title claims abstract description 96
- 239000000203 mixture Substances 0.000 title claims description 141
- 239000008393 encapsulating agent Substances 0.000 claims abstract description 187
- 238000000576 coating method Methods 0.000 claims abstract description 73
- 239000011248 coating agent Substances 0.000 claims abstract description 69
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims abstract description 57
- 239000007921 spray Substances 0.000 claims abstract description 21
- 239000000047 product Substances 0.000 claims description 235
- 244000005700 microbiome Species 0.000 claims description 42
- 235000000346 sugar Nutrition 0.000 claims description 40
- 108010005094 Advanced Glycation End Products Proteins 0.000 claims description 39
- 241000196324 Embryophyta Species 0.000 claims description 37
- 239000003921 oil Substances 0.000 claims description 35
- 235000019198 oils Nutrition 0.000 claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 239000000796 flavoring agent Substances 0.000 claims description 33
- 235000019634 flavors Nutrition 0.000 claims description 31
- 239000002028 Biomass Substances 0.000 claims description 30
- 238000001035 drying Methods 0.000 claims description 30
- 230000008569 process Effects 0.000 claims description 30
- 235000001014 amino acid Nutrition 0.000 claims description 26
- 229940024606 amino acid Drugs 0.000 claims description 26
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 235000018102 proteins Nutrition 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 239000001993 wax Substances 0.000 claims description 25
- 239000000839 emulsion Substances 0.000 claims description 23
- 241001465754 Metazoa Species 0.000 claims description 21
- 239000012530 fluid Substances 0.000 claims description 20
- 235000013305 food Nutrition 0.000 claims description 19
- 239000007787 solid Substances 0.000 claims description 19
- 239000003963 antioxidant agent Substances 0.000 claims description 18
- 235000006708 antioxidants Nutrition 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 18
- 239000003760 tallow Substances 0.000 claims description 17
- 230000003078 antioxidant effect Effects 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 13
- 229940088594 vitamin Drugs 0.000 claims description 13
- 229930003231 vitamin Natural products 0.000 claims description 13
- 239000011782 vitamin Substances 0.000 claims description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- 235000013343 vitamin Nutrition 0.000 claims description 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 11
- 229930195729 fatty acid Natural products 0.000 claims description 11
- 239000000194 fatty acid Substances 0.000 claims description 11
- 150000004665 fatty acids Chemical class 0.000 claims description 11
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 11
- 239000011707 mineral Substances 0.000 claims description 11
- 235000004977 Brassica sinapistrum Nutrition 0.000 claims description 10
- -1 coenzymeQ Chemical compound 0.000 claims description 10
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 10
- 239000000413 hydrolysate Substances 0.000 claims description 10
- 235000013336 milk Nutrition 0.000 claims description 10
- 239000008267 milk Substances 0.000 claims description 10
- 210000004080 milk Anatomy 0.000 claims description 10
- 238000012545 processing Methods 0.000 claims description 10
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 9
- 108010046377 Whey Proteins Proteins 0.000 claims description 9
- 102000007544 Whey Proteins Human genes 0.000 claims description 9
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 9
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 9
- 241001467333 Thraustochytriaceae Species 0.000 claims description 8
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 8
- 150000001720 carbohydrates Chemical class 0.000 claims description 8
- 235000014633 carbohydrates Nutrition 0.000 claims description 8
- 238000005354 coacervation Methods 0.000 claims description 8
- 239000005515 coenzyme Substances 0.000 claims description 8
- 239000006185 dispersion Substances 0.000 claims description 8
- 229940088597 hormone Drugs 0.000 claims description 8
- 239000005556 hormone Substances 0.000 claims description 8
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 8
- 239000000944 linseed oil Substances 0.000 claims description 8
- 235000021388 linseed oil Nutrition 0.000 claims description 8
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 claims description 7
- 235000006008 Brassica napus var napus Nutrition 0.000 claims description 7
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 claims description 7
- 244000188595 Brassica sinapistrum Species 0.000 claims description 7
- 238000012695 Interfacial polymerization Methods 0.000 claims description 7
- 241000186660 Lactobacillus Species 0.000 claims description 7
- 108010073771 Soybean Proteins Proteins 0.000 claims description 7
- 240000008042 Zea mays Species 0.000 claims description 7
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 7
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 7
- 239000011324 bead Substances 0.000 claims description 7
- 235000005822 corn Nutrition 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 229940039696 lactobacillus Drugs 0.000 claims description 7
- 239000008601 oleoresin Substances 0.000 claims description 7
- 238000005507 spraying Methods 0.000 claims description 7
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 241000199914 Dinophyceae Species 0.000 claims description 6
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 6
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 6
- 235000004431 Linum usitatissimum Nutrition 0.000 claims description 6
- 240000006240 Linum usitatissimum Species 0.000 claims description 6
- 235000021355 Stearic acid Nutrition 0.000 claims description 6
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 6
- 239000005018 casein Substances 0.000 claims description 6
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 6
- 235000021240 caseins Nutrition 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 6
- 230000018044 dehydration Effects 0.000 claims description 6
- 238000006297 dehydration reaction Methods 0.000 claims description 6
- 238000001125 extrusion Methods 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 235000021588 free fatty acids Nutrition 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 6
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 6
- 229960004488 linolenic acid Drugs 0.000 claims description 6
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 6
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 6
- 229940001941 soy protein Drugs 0.000 claims description 6
- 238000009987 spinning Methods 0.000 claims description 6
- 239000008117 stearic acid Substances 0.000 claims description 6
- 235000020357 syrup Nutrition 0.000 claims description 6
- 239000006188 syrup Substances 0.000 claims description 6
- 235000021119 whey protein Nutrition 0.000 claims description 6
- 235000010469 Glycine max Nutrition 0.000 claims description 5
- 108010030975 Polyketide Synthases Proteins 0.000 claims description 5
- 235000019519 canola oil Nutrition 0.000 claims description 5
- 239000000828 canola oil Substances 0.000 claims description 5
- 239000007795 chemical reaction product Substances 0.000 claims description 5
- 238000010668 complexation reaction Methods 0.000 claims description 5
- 238000001879 gelation Methods 0.000 claims description 5
- 239000002502 liposome Substances 0.000 claims description 5
- 239000002417 nutraceutical Substances 0.000 claims description 5
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 5
- 235000015277 pork Nutrition 0.000 claims description 5
- 230000006641 stabilisation Effects 0.000 claims description 5
- 238000011105 stabilization Methods 0.000 claims description 5
- 238000010557 suspension polymerization reaction Methods 0.000 claims description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- 244000068988 Glycine max Species 0.000 claims description 4
- 241000238631 Hexapoda Species 0.000 claims description 4
- 235000019687 Lamb Nutrition 0.000 claims description 4
- 241000235575 Mortierella Species 0.000 claims description 4
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 4
- 235000019485 Safflower oil Nutrition 0.000 claims description 4
- 235000019486 Sunflower oil Nutrition 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- 229930003448 Vitamin K Natural products 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 229960005375 lutein Drugs 0.000 claims description 4
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 4
- 239000004006 olive oil Substances 0.000 claims description 4
- 235000008390 olive oil Nutrition 0.000 claims description 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 4
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 4
- 235000005713 safflower oil Nutrition 0.000 claims description 4
- 239000003813 safflower oil Substances 0.000 claims description 4
- 239000002600 sunflower oil Substances 0.000 claims description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- 239000008158 vegetable oil Substances 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 235000019168 vitamin K Nutrition 0.000 claims description 4
- 239000011712 vitamin K Substances 0.000 claims description 4
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 4
- 229940046010 vitamin k Drugs 0.000 claims description 4
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical class OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 claims description 3
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 claims description 3
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- 235000007173 Abies balsamea Nutrition 0.000 claims description 3
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 3
- 244000105624 Arachis hypogaea Species 0.000 claims description 3
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 3
- 235000018262 Arachis monticola Nutrition 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 3
- 239000004857 Balsam Substances 0.000 claims description 3
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 3
- 241000186012 Bifidobacterium breve Species 0.000 claims description 3
- 241001608472 Bifidobacterium longum Species 0.000 claims description 3
- 235000007689 Borago officinalis Nutrition 0.000 claims description 3
- 240000004355 Borago officinalis Species 0.000 claims description 3
- 241000219198 Brassica Species 0.000 claims description 3
- 235000003351 Brassica cretica Nutrition 0.000 claims description 3
- 240000002791 Brassica napus Species 0.000 claims description 3
- 235000003343 Brassica rupestris Nutrition 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 3
- 244000020518 Carthamus tinctorius Species 0.000 claims description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 3
- 235000010523 Cicer arietinum Nutrition 0.000 claims description 3
- 244000045195 Cicer arietinum Species 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- 229920000742 Cotton Polymers 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- 244000299507 Gossypium hirsutum Species 0.000 claims description 3
- 244000020551 Helianthus annuus Species 0.000 claims description 3
- 235000003222 Helianthus annuus Nutrition 0.000 claims description 3
- 244000018716 Impatiens biflora Species 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 3
- 241000186713 Lactobacillus amylovorus Species 0.000 claims description 3
- 240000001929 Lactobacillus brevis Species 0.000 claims description 3
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims description 3
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 3
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 3
- 244000199866 Lactobacillus casei Species 0.000 claims description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 3
- 241000218492 Lactobacillus crispatus Species 0.000 claims description 3
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 3
- 241000509544 Lactobacillus gallinarum Species 0.000 claims description 3
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 3
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 3
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 3
- 241001468157 Lactobacillus johnsonii Species 0.000 claims description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 239000004166 Lanolin Substances 0.000 claims description 3
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 claims description 3
- 244000043158 Lens esculenta Species 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- 241000192130 Leuconostoc mesenteroides Species 0.000 claims description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 3
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 3
- 244000061176 Nicotiana tabacum Species 0.000 claims description 3
- 241000219925 Oenothera Species 0.000 claims description 3
- 235000004496 Oenothera biennis Nutrition 0.000 claims description 3
- 240000007817 Olea europaea Species 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000021314 Palmitic acid Nutrition 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 3
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 claims description 3
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 claims description 3
- 240000000111 Saccharum officinarum Species 0.000 claims description 3
- 235000007201 Saccharum officinarum Nutrition 0.000 claims description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- 229920001800 Shellac Polymers 0.000 claims description 3
- 244000057717 Streptococcus lactis Species 0.000 claims description 3
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 3
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- 244000042324 Trifolium repens Species 0.000 claims description 3
- 235000013540 Trifolium repens var repens Nutrition 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 3
- 229930003451 Vitamin B1 Natural products 0.000 claims description 3
- 229930003471 Vitamin B2 Natural products 0.000 claims description 3
- 229930003537 Vitamin B3 Natural products 0.000 claims description 3
- 229930003571 Vitamin B5 Natural products 0.000 claims description 3
- 229930003316 Vitamin D Natural products 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- 239000005862 Whey Substances 0.000 claims description 3
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims description 3
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims description 3
- 229920002494 Zein Polymers 0.000 claims description 3
- 108010055615 Zein Proteins 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 3
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 3
- 235000021342 arachidonic acid Nutrition 0.000 claims description 3
- 229940114079 arachidonic acid Drugs 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- 239000012179 bayberry wax Substances 0.000 claims description 3
- 235000013871 bee wax Nutrition 0.000 claims description 3
- 235000015278 beef Nutrition 0.000 claims description 3
- 239000012166 beeswax Substances 0.000 claims description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 239000011648 beta-carotene Substances 0.000 claims description 3
- 235000013734 beta-carotene Nutrition 0.000 claims description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 229960002747 betacarotene Drugs 0.000 claims description 3
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 3
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 3
- 229960002079 calcium pantothenate Drugs 0.000 claims description 3
- 239000004204 candelilla wax Substances 0.000 claims description 3
- 235000013868 candelilla wax Nutrition 0.000 claims description 3
- 229940073532 candelilla wax Drugs 0.000 claims description 3
- 229960004203 carnitine Drugs 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- 239000012185 ceresin wax Substances 0.000 claims description 3
- 239000011651 chromium Substances 0.000 claims description 3
- 229910052804 chromium Inorganic materials 0.000 claims description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 3
- 235000013861 fat-free Nutrition 0.000 claims description 3
- 235000004426 flaxseed Nutrition 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 235000004554 glutamine Nutrition 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 239000010513 hydrogenated corn oil Substances 0.000 claims description 3
- 239000010514 hydrogenated cottonseed oil Substances 0.000 claims description 3
- 239000008173 hydrogenated soybean oil Substances 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 3
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 3
- 229940017800 lactobacillus casei Drugs 0.000 claims description 3
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 3
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000019388 lanolin Nutrition 0.000 claims description 3
- 229940039717 lanolin Drugs 0.000 claims description 3
- 235000019136 lipoic acid Nutrition 0.000 claims description 3
- 235000012680 lutein Nutrition 0.000 claims description 3
- 239000001656 lutein Substances 0.000 claims description 3
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 3
- 235000012661 lycopene Nutrition 0.000 claims description 3
- 239000001751 lycopene Substances 0.000 claims description 3
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 3
- 229960004999 lycopene Drugs 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- 239000012184 mineral wax Substances 0.000 claims description 3
- 239000011733 molybdenum Substances 0.000 claims description 3
- 229910052750 molybdenum Inorganic materials 0.000 claims description 3
- 235000010460 mustard Nutrition 0.000 claims description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 3
- LYRFLYHAGKPMFH-UHFFFAOYSA-N octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(N)=O LYRFLYHAGKPMFH-UHFFFAOYSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 235000021313 oleic acid Nutrition 0.000 claims description 3
- 239000012186 ozocerite Substances 0.000 claims description 3
- 239000012188 paraffin wax Substances 0.000 claims description 3
- 235000020232 peanut Nutrition 0.000 claims description 3
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims description 3
- 239000012169 petroleum derived wax Substances 0.000 claims description 3
- 235000019381 petroleum wax Nutrition 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- 229920005862 polyol Polymers 0.000 claims description 3
- 229920000098 polyolefin Polymers 0.000 claims description 3
- 150000003077 polyols Chemical class 0.000 claims description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 239000011669 selenium Substances 0.000 claims description 3
- 229910052711 selenium Inorganic materials 0.000 claims description 3
- 235000013874 shellac Nutrition 0.000 claims description 3
- 239000004208 shellac Substances 0.000 claims description 3
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 3
- 229940113147 shellac Drugs 0.000 claims description 3
- 235000020183 skimmed milk Nutrition 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 claims description 3
- 229960003495 thiamine Drugs 0.000 claims description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 3
- 229960002663 thioctic acid Drugs 0.000 claims description 3
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 claims description 3
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- 239000012178 vegetable wax Substances 0.000 claims description 3
- 235000019155 vitamin A Nutrition 0.000 claims description 3
- 239000011719 vitamin A Substances 0.000 claims description 3
- 235000010374 vitamin B1 Nutrition 0.000 claims description 3
- 239000011691 vitamin B1 Substances 0.000 claims description 3
- 235000019164 vitamin B2 Nutrition 0.000 claims description 3
- 239000011716 vitamin B2 Substances 0.000 claims description 3
- 235000019160 vitamin B3 Nutrition 0.000 claims description 3
- 239000011708 vitamin B3 Substances 0.000 claims description 3
- 239000011675 vitamin B5 Substances 0.000 claims description 3
- 235000009492 vitamin B5 Nutrition 0.000 claims description 3
- 235000019158 vitamin B6 Nutrition 0.000 claims description 3
- 239000011726 vitamin B6 Substances 0.000 claims description 3
- 235000019166 vitamin D Nutrition 0.000 claims description 3
- 239000011710 vitamin D Substances 0.000 claims description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 3
- 229940045997 vitamin a Drugs 0.000 claims description 3
- 229940011671 vitamin b6 Drugs 0.000 claims description 3
- 229940046008 vitamin d Drugs 0.000 claims description 3
- 235000010930 zeaxanthin Nutrition 0.000 claims description 3
- 229940043269 zeaxanthin Drugs 0.000 claims description 3
- 239000001775 zeaxanthin Substances 0.000 claims description 3
- 239000005019 zein Substances 0.000 claims description 3
- 229940093612 zein Drugs 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 3
- 241001133760 Acoelorraphe Species 0.000 claims description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 2
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 2
- 238000012239 gene modification Methods 0.000 claims description 2
- 230000005017 genetic modification Effects 0.000 claims description 2
- 235000013617 genetically modified food Nutrition 0.000 claims description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 1
- 229920000642 polymer Polymers 0.000 description 42
- 239000000463 material Substances 0.000 description 39
- 239000002904 solvent Substances 0.000 description 36
- 239000002245 particle Substances 0.000 description 28
- 239000000243 solution Substances 0.000 description 26
- 238000005538 encapsulation Methods 0.000 description 23
- 239000007788 liquid Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 239000011162 core material Substances 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000012071 phase Substances 0.000 description 17
- 239000000126 substance Substances 0.000 description 15
- 241000894007 species Species 0.000 description 14
- 239000003925 fat Substances 0.000 description 13
- 235000019197 fats Nutrition 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 238000001694 spray drying Methods 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- 239000011257 shell material Substances 0.000 description 9
- 150000008163 sugars Chemical class 0.000 description 9
- 239000000284 extract Substances 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 239000003570 air Substances 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 235000013601 eggs Nutrition 0.000 description 6
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 241000233675 Thraustochytrium Species 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 239000000686 essence Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 239000003094 microcapsule Substances 0.000 description 5
- 239000004005 microsphere Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 235000011888 snacks Nutrition 0.000 description 5
- 235000021055 solid food Nutrition 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 235000019499 Citrus oil Nutrition 0.000 description 4
- 244000018436 Coriandrum sativum Species 0.000 description 4
- 235000009421 Myristica fragrans Nutrition 0.000 description 4
- 235000008184 Piper nigrum Nutrition 0.000 description 4
- 244000203593 Piper nigrum Species 0.000 description 4
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 4
- 235000013614 black pepper Nutrition 0.000 description 4
- 239000010500 citrus oil Substances 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 239000006052 feed supplement Substances 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- JARKCYVAAOWBJS-UHFFFAOYSA-N hexanal Chemical compound CCCCCC=O JARKCYVAAOWBJS-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 235000021056 liquid food Nutrition 0.000 description 4
- 239000011859 microparticle Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 235000019645 odor Nutrition 0.000 description 4
- 238000005191 phase separation Methods 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 238000000935 solvent evaporation Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 241000199912 Crypthecodinium cohnii Species 0.000 description 3
- 241000195493 Cryptophyta Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 235000013628 Lantana involucrata Nutrition 0.000 description 3
- 240000005183 Lantana involucrata Species 0.000 description 3
- 241001491708 Macrocystis Species 0.000 description 3
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 3
- 229940123973 Oxygen scavenger Drugs 0.000 description 3
- 244000178231 Rosmarinus officinalis Species 0.000 description 3
- 241000233671 Schizochytrium Species 0.000 description 3
- 241001491678 Ulkenia Species 0.000 description 3
- 235000019568 aromas Nutrition 0.000 description 3
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000007757 hot melt coating Methods 0.000 description 3
- 239000012943 hotmelt Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000010525 oxidative degradation reaction Methods 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 240000002234 Allium sativum Species 0.000 description 2
- 244000099147 Ananas comosus Species 0.000 description 2
- 235000007119 Ananas comosus Nutrition 0.000 description 2
- 240000007087 Apium graveolens Species 0.000 description 2
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 2
- 235000010591 Appio Nutrition 0.000 description 2
- 235000003092 Artemisia dracunculus Nutrition 0.000 description 2
- 240000001851 Artemisia dracunculus Species 0.000 description 2
- 241000206761 Bacillariophyta Species 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 244000017106 Bixa orellana Species 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- 240000004160 Capsicum annuum Species 0.000 description 2
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 2
- 240000008574 Capsicum frutescens Species 0.000 description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 240000000560 Citrus x paradisi Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 235000002787 Coriandrum sativum Nutrition 0.000 description 2
- 241001137251 Corvidae Species 0.000 description 2
- 241000199913 Crypthecodinium Species 0.000 description 2
- 235000007129 Cuminum cyminum Nutrition 0.000 description 2
- 244000304337 Cuminum cyminum Species 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- 244000008991 Curcuma longa Species 0.000 description 2
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 241000989765 Diplophrys Species 0.000 description 2
- 240000002943 Elettaria cardamomum Species 0.000 description 2
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 2
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 2
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 2
- 240000006927 Foeniculum vulgare Species 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 241001467308 Labyrinthuloides Species 0.000 description 2
- 241000220225 Malus Species 0.000 description 2
- 235000011430 Malus pumila Nutrition 0.000 description 2
- 235000015103 Malus silvestris Nutrition 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 241000907999 Mortierella alpina Species 0.000 description 2
- 240000005561 Musa balbisiana Species 0.000 description 2
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 2
- 244000270834 Myristica fragrans Species 0.000 description 2
- 235000010676 Ocimum basilicum Nutrition 0.000 description 2
- 240000007926 Ocimum gratissimum Species 0.000 description 2
- 235000011203 Origanum Nutrition 0.000 description 2
- 240000000783 Origanum majorana Species 0.000 description 2
- 235000009827 Prunus armeniaca Nutrition 0.000 description 2
- 244000018633 Prunus armeniaca Species 0.000 description 2
- 240000005809 Prunus persica Species 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 235000014443 Pyrus communis Nutrition 0.000 description 2
- 240000001987 Pyrus communis Species 0.000 description 2
- 240000007651 Rubus glaucus Species 0.000 description 2
- 235000011034 Rubus glaucus Nutrition 0.000 description 2
- 235000009122 Rubus idaeus Nutrition 0.000 description 2
- 241001466451 Stramenopiles Species 0.000 description 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 2
- 244000223014 Syzygium aromaticum Species 0.000 description 2
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 2
- 235000007303 Thymus vulgaris Nutrition 0.000 description 2
- 240000002657 Thymus vulgaris Species 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 240000006909 Tilia x europaea Species 0.000 description 2
- 240000000851 Vaccinium corymbosum Species 0.000 description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 235000009499 Vanilla fragrans Nutrition 0.000 description 2
- 244000263375 Vanilla tahitensis Species 0.000 description 2
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 150000001299 aldehydes Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000012665 annatto Nutrition 0.000 description 2
- 239000010362 annatto Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000008452 baby food Nutrition 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000001511 capsicum annuum Substances 0.000 description 2
- 239000001390 capsicum minimum Substances 0.000 description 2
- 235000005300 cardamomo Nutrition 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 235000010675 chips/crisps Nutrition 0.000 description 2
- 235000017803 cinnamon Nutrition 0.000 description 2
- 239000010630 cinnamon oil Substances 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000014510 cooky Nutrition 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000015897 energy drink Nutrition 0.000 description 2
- 235000010350 erythorbic acid Nutrition 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000004611 garlic Nutrition 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940026239 isoascorbic acid Drugs 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000001115 mace Substances 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 239000001683 mentha spicata herb oil Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000010466 nut oil Substances 0.000 description 2
- 235000019488 nut oil Nutrition 0.000 description 2
- 239000001702 nutmeg Substances 0.000 description 2
- 235000014571 nuts Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 235000015108 pies Nutrition 0.000 description 2
- 239000001931 piper nigrum l. white Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000020991 processed meat Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 229940075579 propyl gallate Drugs 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000014102 seafood Nutrition 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000019721 spearmint oil Nutrition 0.000 description 2
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 2
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 2
- 239000001585 thymus vulgaris Substances 0.000 description 2
- 235000008371 tortilla/corn chips Nutrition 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 239000009637 wintergreen oil Substances 0.000 description 2
- 241000003610 Aplanochytrium Species 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241000178280 Aureococcus Species 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 241001655287 Chlamydomyxa Species 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 241000384555 Chromulinales Species 0.000 description 1
- 241000206751 Chrysophyceae Species 0.000 description 1
- 241001633026 Coenocystis Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 241001494734 Dictyochales Species 0.000 description 1
- 241001462977 Elina Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 241000224472 Eustigmatophyceae Species 0.000 description 1
- 241001466486 Hibberdiales Species 0.000 description 1
- 241001306467 Hydrurales Species 0.000 description 1
- 238000012696 Interfacial polycondensation Methods 0.000 description 1
- 241000003482 Japonochytrium Species 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 241001491670 Labyrinthula Species 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 241000907923 Mortierella schmuckeri Species 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 241000233654 Oomycetes Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241000472328 Parmales Species 0.000 description 1
- 241001494726 Pedinellales Species 0.000 description 1
- 241001494851 Pelagococcus Species 0.000 description 1
- 241001494897 Pelagomonas Species 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 229920001131 Pulp (paper) Polymers 0.000 description 1
- 241001518925 Raphidophyceae Species 0.000 description 1
- 241000520590 Reticulosphaera Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000193082 Sarcinochrysidales Species 0.000 description 1
- 239000003568 Sodium, potassium and calcium salts of fatty acids Substances 0.000 description 1
- 241000864178 Sorodiplophrys Species 0.000 description 1
- 241000482268 Zea mays subsp. mays Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 108010038836 acidolin Proteins 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000013969 calcium salts of fatty acid Nutrition 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008162 cooking oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000002036 drum drying Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 235000014089 extruded snacks Nutrition 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000003861 general physiology Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000003869 genetically modified organism Nutrition 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000014168 granola/muesli bars Nutrition 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010952 in-situ formation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000005555 metalworking Methods 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 235000012459 muffins Nutrition 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 235000014594 pastries Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940109529 pomegranate extract Drugs 0.000 description 1
- 235000013606 potato chips Nutrition 0.000 description 1
- 235000019684 potato crisps Nutrition 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 235000012434 pretzels Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 235000014438 salad dressings Nutrition 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 235000009561 snack bars Nutrition 0.000 description 1
- 235000012177 snack cakes Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 229940071440 soy protein isolate Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000006032 tissue transformation Effects 0.000 description 1
- 235000012776 toaster pastry Nutrition 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 235000012773 waffles Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/179—Colouring agents, e.g. pigmenting or dyeing agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/184—Hormones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/20—Shaping or working-up of animal feeding-stuffs by moulding, e.g. making cakes or briquettes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/25—Shaping or working-up of animal feeding-stuffs by extrusion
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/70—Fixation, conservation, or encapsulation of flavouring agents
- A23L27/72—Encapsulation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
Definitions
- the invention relates to encapsulated labile compounds, including polyunsaturated fatty acids, and methods of making the same.
- Labile compounds and compositions such as polyunsaturated fatty acids (PUFAs), vitamins, minerals, antioxidants, hormones, amino acids, proteins, carbohydrates, coenzymes, and flavor agents, sensitive to any number of factors, can lose biological or other desired activity when unprotected.
- PUFAs polyunsaturated fatty acids
- products for example, decomposition products, degradation products, and oxidation products
- Microcapsulating unstable compounds can protect them from undesirable chemical, physical, or biological change or breakdown while retaining their efficacy, such as biological or physiological efficacy.
- Microcapsules can exist in powdered form and comprise roughly spherical particles that contain an encapsulated (entrapped) substance.
- the particle usually has some type of shell, often a polymeric shell, such as a polypeptide or polysaccharide shell, and the encapsulated active product is located within the shell.
- Microencapsulation of a liquid, such as an oil allows the formation of a particle that presents a dry outer surface with an entrained oil. Often the particles are a free-flowing powder. Microencapsulation therefore effectively enables the conversion of liquids to powders.
- microencapsulation Numerous techniques for microencapsulation are known depending on the nature of the encapsulated substance and on the type of shell material used. Methods typically involve solidifying emulsified liquid droplets by changing temperature, evaporating solvent, or adding chemical cross-linking agents. Such methods include, for example, spray drying, interfacial polymerization, hot melt encapsulation, phase separation encapsulation (solvent removal and solvent evaporation), spontaneous emulsion, solvent evaporation microencapsulation, solvent removal microencapsulation, coacervation, and low temperature microsphere formation and phase inversion nanoencapsulation (PIN). Microencapsulation is suitable for drugs, vitamins and food supplements since this process is adaptable by varying the encapsulation ingredients and conditions.
- microencapsulated forms of fats or oils such as vegetable and marine oils, which contain PUFAs.
- Such microencapsulated forms would benefit from the properties of digestibility, stability, resistance to chemical, physical, or biological change or breakdown.
- Microencapsulated oils could conveniently be provided as a free flowing powdered form. Such a powder can be readily mixed with other dry or liquid components to form a useful product.
- microencapsulate can be limited by factors due to the nature of the microencapsulation process or the compound or composition to be encapsulated. Such factors could include pH, temperature, uniformity, viscosity, hydrophobicity, molecular weight, and the like. Additionally, a given microencapsulation process may have inherent limitations. For example, in microencapsulation techniques in which heat is used for drying, low-boiling point aromatics can be lost during the drying process. Additionally, the core may adhere to the surface of the encapsulation material, presenting a potential for increased oxidation and changes in the flavor balance of the finished product. In some cases, storage conditions must be carefully controlled to avoid an increase in the water activity and therefore the stability of the capsule and retention of volatiles within the capsule.
- the feed inlet temperature may not be high enough and result in incomplete drying and sticking in the drying chamber or clump formation in storage. Particulate inconsistencies may also occur under some process conditions. At temperatures that are too low, the particles may balloon and cracks can form in the surface of the particles. This may cause loss of volatile compounds and compromise the quality of the final product. Yet another drawback is that the coatings produced are often water-soluble and temperature sensitive. The present inventors have recognized the foregoing problems and that there is a need, therefore, to provide additional processes for encapsulation of compounds and compositions susceptible to chemical, physical, or biological change or breakdown.
- the present invention is directed to products comprising labile compounds, such as polyunsaturated fatty acids, and having first and second encapsulants, as well as methods of making the same.
- the invention provides a product comprising a composition comprising a labile compound; a first encapsulant of the composition; and a second encapsulant of the first encapsulant, wherein the second encapsulant is a prill coating, wherein the product further comprises a Maillard reaction product.
- the invention also provides a product comprising a composition comprising a labile compound; a first encapsulant of the composition; and a second encapsulant of the first encapsulant, wherein the product further comprises a Maillard reaction product formed by contacting the first encapsulant with the second encapsulant.
- the invention further provides a product comprising a composition comprising a labile compound; a first encapsulant of the composition; and a second encapsulant of the first encapsulant, wherein the second encapsulant further comprises a Maillard reaction product.
- the invention also provides a product comprising a composition comprising a labile compound; a first encapsulant of the composition; and a second encapsulant of the first encapsulant, wherein the product further comprises a Maillard reaction product formed in a non-aqueous environment.
- the labile compound includes polyunsaturated fatty acid, a vitamin, a mineral, an antioxidant, a hormone, an amino acid, a protein, a carbohydrate, a coenzyme, a flavor agent, and mixtures of the foregoing.
- the invention also provides a product comprising a composition comprising a labile compound selected from the group consisting of a polyunsaturated fatty acid, a vitamin, a mineral, an antioxidant, a hormone, an amino acid, a protein, a carbohydrate, a coenzyme, and mixtures thereof; a first encapsulant of the composition; and a prill coating on the first encapsulant.
- a labile compound selected from the group consisting of a polyunsaturated fatty acid, a vitamin, a mineral, an antioxidant, a hormone, an amino acid, a protein, a carbohydrate, a coenzyme, and mixtures thereof.
- the labile compound comprises a polyunsaturated fatty acid from a source selected from the group consisting of a plant, an oilseed, a microorganism, an animal, and mixtures of the foregoing.
- the microorganism includes algae, bacteria, fungi and protists.
- the source is selected from the group consisting of plant and oilseed selected from the group consisting of soybean, corn, safflower, sunflower, canola, flax, peanut, mustard, rapeseed, chickpea, cotton, lentil, white clover, olive, palm, borage, evening primrose, linseed and tobacco and mixtures thereof.
- the source includes a genetically modified plant, a genetically modified oilseed, and a genetically modified microorganism, wherein the genetic modification comprises the introduction of polyketide synthase genes.
- the microorganism includes Thraustochytriales, dinoflagellates, and Mortierella. In still other embodiments, the microorganism includes Schizochytrium, Thraustochytrium or a dinoflagellate of the genus Crypthecodinium.
- the animal includes an aquatic animal.
- the labile compound comprises a polyunsaturated fatty acid having a chain length of at least 18 carbons. In other embodiments, the labile compound comprises a polyunsaturated fatty acid including docosahexaenoic acid, omega-3 docosapentaenoic acid, omega-6 docosapentaenoic acid, arachidonic acid, eicosapentaneoic acid, stearidonic acid, linolenic acid, alpha linolenic acid (ALA), gamma linolenic acid (GLA), conjugated linolenic acid (CLA) and mixtures thereof.
- ALA alpha linolenic acid
- GLA gamma linolenic acid
- CLA conjugated linolenic acid
- the labile compound comprises a vitamin selected from the group consisting of Vitamin A, Vitamin D, Vitamin E, Vitamin K, Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B6, Vitamin C, Folic Acid, Vitamin B-12, Biotin, Vitamin B5 and mixtures thereof.
- the labile compound comprises a mineral selected from the group consisting of calcium, iron, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum and mixtures thereof.
- the labile compound comprises an antioxidant selected from the group consisting of lycopene, lutein, zeaxanthin, alpha-lipoic acid, coenzymeQ, beta-carotene and mixtures thereof.
- the labile compound comprises an amino acid selected from the group consisting of arginine, aspartic acid, carnitine, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, SAM-e and mixtures thereof.
- the flavor agent comprises a flavor oil, oleoresin or mixtures thereof.
- the first encapsulant of the composition comprising the labile compound includes a whole cell, a biomass hydrolysate, an oilseed and an encapsulated isolated labile compound.
- the first encapsulant of the composition comprising the labile compound is a whole cell or a biomass hydrolysate derived from microorganisms.
- the microorganism includes Lactococcus lactis, Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus amylovorous, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus rhamnosus, Lactobacillus brevis, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus helveticus, Lactobacillus casei, Lactobacillus delbruckii, Lactobacillus bulgaricus, Lactobacillus plantarum, Lactobacillus GG, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacteriun infantis, Bifidobacter
- the first encapsulant of the composition comprising the labile compound is a dried whole cell.
- the dried whole cell is a spray-dried whole cell.
- the first encapsulant is prepared by a method is selected from the group consisting of fluid bed drying, drum (film) drying, coacervation, interfacial polymerization, fluid bed processing, pan coating, spray gelation, ribbon blending, spinning disk, centrifugal coextrusion, inclusion complexation, emulsion stabilization, spray coating, extrusion, liposome nanoencapsulation, supercritical fluid microencapsulation, suspension polymerization, cold dehydration processes, spray chilling (prilling), and evaporative dispersion processes.
- the prill coating is selected from the group consisting of a fatty acid monoglyceride; a fatty acid diglyceride; a fatty acid triglyceride; a free fatty acid; tallow; lard; beeswax; lanolin; shell wax; insect wax; vegetable wax, camauba wax; candelilla wax; bayberry wax; sugar cane wax; mineral wax; paraffin microcrystalline petroleum wax; ozocerite wax; ceresin wax; montan synthetic wax, low molecular weight polyolefin; polyol ether-esters, sorbitol; Fischer.-Tropsch process synthetic wax; rosin; balsam; shellac; stearylamide; ethylenebisstearylamide; hydrogenated castor oil; esters of pentaerythritol; mono and tetra esters of stearic acid; vegetable oil; a hydrogenated vegetable oil; and mixtures and derivatives of the foregoing.
- the prill coating is a free fatty acid selected from the group consisting of stearic acid, palmitic acid, and oleic acid.
- the tallow includes sbeef tallow, mutton tallow, pork tallow, and lamb tallow.
- the hydrogenated vegetable oil includes hydrogenated cottonseed oil, hydrogenated sunflower oil, hydrogenated safflower oil, hydrogenated soybean oil, hydrogenated corn oil, hydrogenated olive oil, hydrogenated canola oil, hydrogenated linseed oil, hydrogenated flaxseed oil.
- the prill coating further comprises a fat-soluble or fat dispersible oxygen scavenger, or a fat-soluble or fat dispersible antioxidant.
- the prill coating further comprises a colorant.
- the Maillard reaction product includes a reaction product of a reducing sugar and a protein selected from the group consisting of casein, whey solids, whey protein isolate, soy protein, skim milk powder, hydrolyzed casein, hydrolyzed whey protein, hydrolyzed soy protein, non-fat milk solids, gelatin, zein, and albumin.
- the Maillard reaction product includes a reaction product of a protein and a reducing sugar selected from the group consisting of fructose, glucose, glyceraldehyde, lactose, arabinose, maltodextrin, corn syrup solids and maltose.
- the invention also provides a product selected from the group consisting of a food product, a cosmetic product, a phannaceutical product, a nutraceutical product, and an industrial product, in which the product comprises a product comprising a composition comprising a labile compound; a first encapsulant of the composition; and a second encapsulant of the first encapsulant, wherein the second encapsulant is a prill coating, wherein the product further comprises a Maillard reaction product.
- the food product includes liquid food products or solid food products.
- Liquid food products include beverages, infant formula, liquid meals, liquid eggs, milk products, and multivitamin syrups. Beverages include energy drinks, fruit juices, and milk.
- Solid food products include baby food, yogurt, cheese, cereal, powdered mixes, baked goods, food bars, and processed meats.
- the product is insoluble in water. In other embodiments the product is physically stable for at least about 30 days, or oxidatively stable for at least about 30 days.
- the Maillard reaction product provides a desirable flavor to the product, a desirable aroma to the product, or antioxidant protection to the product.
- the Maillard reaction product is present in the outer 75% of the second encapsulant.
- the product has a particle size of between about 10 ⁇ m and about 3000 ⁇ m.
- the product comprises labile compound in an amount between about 1 weight percent and about 50 weight percent.
- the product is in a form selected from the group consisting of a free-flowing powder, a bead, a chip, and a flake.
- the invention also provides a method for preparing a product comprising encapsulating a first encapsulated product in the presence of an amino acid source and a reducing sugar to form a second encapsulated product, whereby Maillard reaction products are formed, and wherein the first encapsulated product comprises an encapsulant of a labile compound.
- the method further comprises handling the labile compound under conditions that reduce oxidative degradation prior to encapsulation.
- the first encapsulated product comprises the amino acid source and the reducing sugar.
- the method further comprising processing the second encapsulated product into a particulate form.
- the processing includes fluid bed drying, drum (film) drying, coacervation, interfacial polymerization, fluid bed processing, pan coating, spray gelation, ribbon blending, spinning disk, centrifugal coextrusion, inclusion complexation, emulsion stabilization, spray coating, extrusion, liposome nanoencapsulation, supercritical fluid microencapsulation, suspension polymerization, cold dehydration processes, spray chilling (prilling), and evaporative dispersion processes.
- the step of encapsulating the first encapsulated product is conducted at a temperature above about 85° C.
- the step of encapsulating the first encapsulated product is conducted for between about 1 minute and about 15 minutes.
- the first encapsulated product is formed by a method comprising emulsifying an aqueous dispersion of a polyunsaturated fatty acid, protein and reducing sugar to form an emulsion; and drying the emulsion to form the first encapsulated product.
- the encapsulating the first encapsulated product comprises contacting the first encapsulated product with a prilling material, spraying the mixture of the first encapsulated product with the prilling material into droplets, and cooling the droplets below the melting point of the prilling material to form the second encapsulated product.
- the prilling material has a melting point in the range of about 32° C. to about 122° C.
- the step of contacting the first encapsulated product with the prilling material is conducted at a temperature above about 85° C.
- the step of contacting the first encapsulated product with the prilling material is conducted for between about 1 minute and about 15 minutes.
- the prilling material is hydrogenated vegetable oil
- the step of contacting the first encapsulated product with the prilling material is conducted for between about 1 minute and about 15 minutes, between 80° C. and 100° C.
- the first encapsulated product comprises about 25 wt % to about 80 wt % labile compound; about 5 wt % to about 25 wt % of an amino acid source; and about 15 wt % to about 70 wt % of a reducing sugar.
- the second encapsulated product is in particulate form and wherein the particulates comprise more than one coated encapsulated product per particulate.
- FIG. 1 shows the improvement in the induction period for a product of the invention (dark grey bars) when compared to a singly encapsulated product (light grey bars).
- the present invention provides encapsulated labile compounds and related methods for their preparation.
- the invention provides a product comprising a composition comprising a labile compound, a first encapsulant of the composition, and a second encapsulant of the first encapsulant, and in some embodiments, the second encapsulant can be a prill coating.
- the product further comprises a Maillard reaction product (MRP).
- MRP Maillard reaction product
- a or “an” refers to one or more of that entity; for example, a PUFA refers to one or more PUFAs or at least one PUFA.
- the terms “a” (or “an”), “one or more” and “at least one” can be used interchangeably herein. It is also to be noted that the terms “comprising”, “including”, and “having” can be used interchangeably.
- the invention is directed to a product that includes a composition comprising a labile compound with a first encapsulant of the composition and a prill coating on the first encapsulant.
- the product further comprises a Maillard reaction product.
- Reference to a prill coating or a second encapsulant being “on the first encapsulant” refers to the prill coating or second encapsulant coating or partially coating the first encapsulant and the composition having a labile compound. It will be recognized that the prill coating or the second encapsulant can either contact the first encapsulant directly or can contact the first encapsulant through one or more intervening layers of other materials.
- the invention is directed to a product that includes a composition comprising a labile compound selected from the group consisting of a polyunsaturated fatty acid, a vitamin, a mineral, an antioxidant, a hormone, an amino acid, a protein, a carbohydrate, a coenzyme, and mixtures thereof.
- the product further includes a first encapsulant of the composition and a prill coating on the first encapsulant.
- the invention is directed to a product that includes a composition comprising a labile compound with a first encapsulant of the composition and a second encapsulant of the first encapsulant.
- the product further comprises a Maillard reaction product formed by contacting the first encapsulant with the second encapsulant.
- the invention is directed to a product that includes a composition comprising a labile compound with a first encapsulant of the composition and a second encapsulant of the first encapsulant.
- the second encapsulant further comprises a Maillard reaction product.
- the invention is directed to a product that includes a composition comprising a labile compound with a first encapsulant of the composition and a second encapsulant of the first encapsulant.
- the product further comprises a Maillard reaction product formed in a non-aqueous environment.
- a labile compound is a compound that will readily undergo a chemical and/or biological change or breakdown; that is, a compound that undergoes a noticeable change under intended use conditions.
- a PUFA in a food product can undergo some degradation in palatability that is noticeable by a consumer of the food product.
- Such conditions can be defined in terms of temperature, storage time, presence of water, and the like.
- Labile compounds include, without limitation, polyunsaturated fatty acids (PUFAs), vitamins, minerals, antioxidants, hormones, amino acids, proteins, carbohydrates, coenzymes, flavor agents and mixtures of the foregoing.
- the labile compound can be selected from PUFAs, vitamins, minerals, antioxidants, hormones, amino acids, proteins, carbohydrates, coenzymes, and mixtures thereof.
- the labile compound can be in the form of a solid particle, a liquid droplet, a gas bubble, or mixtures of these.
- the labile compound is a solid particle, and in another preferred embodiment, the labile compound is a liquid.
- the labile compound is a PUFA.
- a PUFA has a chain length of at least 18 carbons. Such PUFAs are referred to herein as long chain PUFAs or LC PUFAs.
- the PUFA can be docosahexaenoic acid C22:6(n-3) (DHA), omega-3 docosapentaenoic acid C22:5(n-3) (DPA(n-3)), omega-6 docosapentaenoic acid C22:5(n-6) (DPA(n-6)), arachidonic acid C20:4(n-6) (ARA), eicosapentaenoic acid C20:5(n-3) (EPA), stearidonic acid, linolenic acid, alpha linolenic acid (ALA), gamma linolenic acid (GLA), conjugated linolenic acid (CLA) or mixtures thereof.
- DHA docosahexaenoic acid
- DPA(n-3) omega-3 docosapentaenoic acid C22:5(n-3)
- DPA(n-6) omega-6 docosapentaenoic acid C22:
- the PUFAs can be in any of the common forms found in natural lipids including but not limited to triacylglycerols, diacylglycerols, monoacylglycerols, phospholipids, free fatty acids, or in natural or synthetic derivative forms of these fatty acids (e.g. calcium salts of fatty acids, esters of fatty acids, including methyl esters, ethyl esters, and the like).
- Reference to an oil or other composition comprising an LC PUFA as used in the present invention, can refer to either a composition comprising only a single LC PUFA such as DHA or a composition comprising a mixture of LC PUFAs such as DHA and EPA, or DHA and ARA.
- PUFAs can be obtained from or derived from a plant (including oilseeds; as one skilled in the art will appricea, an oilseed is part of a plant), a microorganism, an animal, or mixtures of the foregoing.
- the microorganisms can be algae, bacteria, fungi or protists.
- Microbial sources and methods for growing microorganisms comprising nutrients and/or PUFAs are known in the art (Industrial Microbiology and Biotechnology, 2nd edition, 1999, American Society for Microbiology).
- the microorganisms can be cultured in a fermentation medium in a fermentor.
- PUFAs produced by microorganisms can be used in the methods and compositions of the present invention.
- organisms include those selected from the group consisting of golden algae (such as microorganisms of the kingdom Stramenopiles), green algae, diatoms, dinoflagellates (such as microorganisms of the order Dinophyceae including members of the genus Crypthecodinium such as, for example, Crypthecodinium cohnii ), yeast, and fungi of the genera Mucor and Mortierella, including but not limited to Mortierella alpina and Mortierella sect. schinuckeri.
- Stramenopiles include microalgae and algae-like microorganisms, including the following groups of microorganisms: Hamatores, Proteromonads, Opalines, Develpayella, Diplophrys, Labrinthulids, Thraustochytrids, Biosecids, Oomycetes, Hypochytridiomycetes, Commation, Reticulosphaera, Pelagomonas, Pelagococcus, Ollicola, Aureococcus, Parmales, Diatoms, Xanthophytes, Phaeophytes (brown algae), Eustigmatophytes, Raphidophytes, Synurids, Axodines (including Rhizochromulinaales, Pedinellales, Dictyochales), Chrysorneridales, Sarcinochrysidales, Hydrurales, Hibberdiales, and Chromulinales.
- Axodines including Rh
- the Thraustochytrids include the genera Schizochytrium (species include aggregatum, limnaceum, mangrovei, minutum, octosporum ), Thraustochytrium (species include arudimentale, aureum, benthicola, globosum, kinnei, motivum, multirudimentale, pachyderinum, proliferuin, roseum, striatum
- Ulkenia (species include amoeboidea, kerguelensis, minuta, profunda, radiate, sailens, sarkariana, schizochytrops, visurgensis, yorkensis ), Aplanochytrium (species include haliotidis, kerguelensis, profunda, stocchinoi ), Japonochytrium (species include marinum ), Althornia (species include crouchii ), and Elina (species include marisalba, sinorifica ).
- Suitable microorganisms include those capable of producing lipids comprising the labile compounds omega-3 and/or omega-6 polyunsaturated fatty acids, and in particular microorganisms that are capable of producing DHA, DPA, EPA or ARA) will be described. More particularly, preferred microorganisms are algae, such as Thraustochytrids of the order Thraustochytriales, including Thraustochytrium (including Ulkenia ) and Schizochytrium and including Thraustochytriales which are disclosed in commonly assigned U.S. Pat. Nos. 5,340,594 and 5,340,742, both issued to Barclay, all of which are incorporated herein by reference in their entirety.
- the microorganisms are selected from the group consisting of microorganisms having the identifying characteristics of ATCC number 20888, ATCC number 20889, ATCC number 20890, ATCC number 20891 and ATCC number 20892. Since there is some disagreement among experts as to whether (lkenia is a separate genus from the genus Thraustochytrium, for the purposes of this application, the genus Thraustochytrium will include Ulkenia. Also preferred are strains of Mortierella schmuckeri (e.g., including ATCC 74371) and Mortierella alpina.
- strains of Crypthecodinium cohnii including microorganisms having the identifying characteristics of ATCC Nos. 30021, 30334-30348, 30541-30543, 30555-30557, 30571, 30572, 30772-30775, 30812, 40750, 50050-50060, and 50297-50300.
- Oleaginous microorganisms are also preferred.
- “oleaginous microorganisms” are defined as microorganisms capable of accumulating greater than 20% of the dry weight of their cells in the form of lipids.
- Genetically modified microorganisms that produce PUFAs are also suitable for the present invention. These can include naturally PUFA-producing microorganisms that have been genetically modified as well as microorganisms that do not naturally produce PUFAs but that have been genetically modified to do so.
- Suitable organisms can be obtained from a number of available sources, including by collection from the natural environment.
- the American Type Culture Collection currently lists many publicly available strains of microorganisms identified above.
- any organism, or any specific type of organism includes wild strains, mutants, or recombinant types. Growth conditions in which to culture or grow these organisms are known in the art, and appropriate growth conditions for at least some of these organisms are disclosed in, for example, U.S. Pat. No. 5,130,242, U.S. Pat. No. 5,407,957, U.S. Pat. No. 5,397,591, U.S. Pat. No. 5,492,938, and U.S. Pat. No. 5,711,983, all of which are incorporated herein by reference in their entirety.
- PUFA-producing plants in alternate embodiments, can include those genetically engineered to express genes that produce PUFAs and those that produce PUFAs naturally. Such genes can include genes encoding proteins involved in the classical fatty acid synthase pathways, or genes encoding proteins involved in the PUFA polyketide synthase (PKS) pathway.
- PKS polyketide synthase
- Oilseed crops suitable for use in the present invention include soybeans, corn, safflower, sunflower, canola, flax, peanut, mustard, rapeseed, chickpea, cotton, lentil, white clover, olive, palm oil, borage, evening primrose, linseed, and tobacco that have been genetically modified to produce PUFA as described above.
- Transformation techniques for microorganisms and plants are well-known in the art. Transformation techniques for microorganisms are well known in the art and are discussed, for example, in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Labs Press. A general technique for transformation of dinoflagellates, which can be adapted for use with Crypthecodinium cohnii, is described in detail in Lohuis and Miller, The Plant Journal (1998) 13(3): 427-435. A general technique for genetic transformation of Thraustochytrids is described in detail in U.S. Patent Application Publication No. 20030166207, published Sep. 4, 2003. Methods for the genetic engineering of plants are also well known in the art.
- oilseed plants When oilseed plants are the source of PUFAs, the seeds can be harvested and processed to remove any impurities, debris or indigestible portions from the harvested seeds. Processing steps vary depending on the type of oilseed and are known in the art. Processing steps can include threshing (such as, for example, when soybean seeds are separated from the pods), dehulling (removing the dry outer covering, or husk, of a fruit, seed, or nut), drying, cleaning, grinding, milling and flaking. After the seeds have been processed to remove any impurities, debris or indigestible materials, they can be added to an aqueous solution and then mixed to produce a slurry. In some embodiments, milling, crushing or flaking is performed prior to mixing with water. A slurry produced in this manier can be treated and processed the same way as described for a microbial fermentation broth.
- Another biomass source of nutrients, including PUFAs, in the compositions and methods of the present invention includes an animal source.
- animal sources include aquatic animals (e.g., fish, marine mammals, and crustaceans such as krill and other eupliausids) and animal tissues (e.g., brain, liver, eyes, etc.) and animal products such as eggs or milk. Techniques for recovery of PUFA-containing oils from such sources are known in the art.
- the labile compound is a vitamin, such as, for example, Vitamin A, Vitamin D, Vitamin E, Vitamin K, Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B6, Vitamin C, Folic Acid, Vitamin B-12, Biotin, Vitamin B5 or mixtures thereof.
- the labile compound is mineral, such as, for example, calcium, iron, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, ionic fonns of the foregoing, biologically acceptable salts of the foregoing, or mixtures thereof.
- the labile compound comprises an antioxidant, carotenoid or xanthophyll, such as, for example, lycopene, lutein, zeaxanthin, astaxanthin, alpha-lipoic acid, coenzymeQ, beta-carotene or mixtures thereof.
- an antioxidant carotenoid or xanthophyll, such as, for example, lycopene, lutein, zeaxanthin, astaxanthin, alpha-lipoic acid, coenzymeQ, beta-carotene or mixtures thereof.
- the labile compound is an amino acid, such as, for example, arginine, aspartic acid, carnitine, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, SAM-e or mixtures thereof.
- amino acid such as, for example, arginine, aspartic acid, carnitine, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, SAM-e or mixtures thereof.
- the labile compound comprises a flavor agent, such as a flavor (or essential) oil, oleoresin, other flavoring essence or mixtures thereof.
- flavor oil is generally recognized in the art to be a flavoring aromatic compound and/or oil or extract derived from botanical sources, i.e. leaves, bark, or skin of fruits or vegetables, and which are usually insoluble in water.
- flavor oils include peppermint oil, spearmint oil, cinnamon oil, oil of wintergreen, nut oil, licorice, vanilla, citrus oils, fruit essences and mixtures thereof.
- Citrus oils and fruit essences include apple, apricot, banana, blueberry, cherry, coconut, grape, grapefruit, lemon, lime, orange, pear, peaches, pineapple, plum, raspberry, strawberry, and mixtures thereof.
- Oleoresin extracts of spices includes, for example oleoresin extracts of tarragon, thyme, sage, rosemary, oregano, nutmeg, basil, bay, cardamom flavor, celery, cilantro, cinnamon, clove, coriander, cumin, fennel, garlic, ginger, mace, marjoram, capsicum, black pepper, white pepper, annatto, paprika, turmeric, cajun, and mixtures thereof.
- the first encapsulant is believed to protect the composition comprising the labile compound to reduce the likelihood of or degree to which the labile compound undergoes a chemical, physical, or biological change or breakdown.
- the first encapsulant can form a continuous coating on the composition comprising the labile compound (100% encapsulation) or alternatively, form a non-continuous coating (e.g., at a level that provides substantial coverage of the labile compound, for example, coverage at 80%, 90%, 95%, or 99%).
- the first encapsulant can be a matrix in which the labile compound is entrapped.
- the composition comprising the labile compound with a first encapsulant can be any of an encapsulated composition comprising a labile compound, a whole cell biomass, a biomass hydrolysate, or an oilseed.
- Encapsulation of compositions comprising labile compounds, including PUFAs, with a first encapsulant can be by any method known in the art.
- the composition comprising a labile compound can be spray-dried.
- Other methods for encapsulation are known, such as fluid bed drying, drum (film) drying, coacervation, interfacial polymerization, fluid bed processing, pan coating, spray gelation, ribbon blending, spinning disk, centrifugal coextrusion, inclusion complexation, emulsion stabilization, spray coating, extrusion, liposome nanoencapsulation, supercritical fluid microencapsulation, suspension polymerization, cold dehydration processes, spray cooling/chilling (prilling), evaporative dispersion processes, and methods that take advantage of differential solubility of coatings at varying temperatures.
- the core material to be encapsulated is dispersed or dissolved in a solution.
- the solution is aqueous and the solution includes a polymer.
- the solution or dispersion is pumped through a micronizing nozzle driven by a flow of compressed gas, and the resulting aerosol is suspended in a heated cyclone of air, allowing the solvent to evaporate from the microdroplets.
- the solidified microparticles pass into a second chamber and are trapped in a collection flask.
- Interfacial polycondensation is used to encapsulate a core material in the following manner.
- One monomer and the core material are dissolved in a solvent.
- a second monomer is dissolved in a second solvent (typically aqueous) which is immiscible with the first.
- An emulsion is formed by suspending the first solution in the second solution by stirring. Once the emulsion is stabilized, an initiator is added to the aqueous phase causing interfacial polymerization at the interface of each droplet of emulsion.
- the core material is added to molten polymer.
- This mixture is suspended as molten droplets in a nonsolvent for the polymer (often oil-based) which has been heated to approximately 10° C. above the melting point of the polymer.
- the emulsion is maintained through vigorous stirring while the nonsolvent bath is quickly cooled below the glass transition of the polymer, causing the molten droplets to solidify and entrap the core material.
- a polymer In solvent evaporation encapsulation, a polymer is typically dissolved in a water immiscible organic solvent and the material to be encapsulated is added to the polymer solution as a suspension or solution in organic solvent. An emulsion is formed by adding this suspension or solution to a vessel of vigorously stirred water (often containing a surface active agent to stabilize the emulsion). The organic solvent is evaporated while continuing to stir. Evaporation results in precipitation of the polymer, forming solid microcapsules containing core material.
- the solvent evaporation process is designed to entrap a liquid core material in a polymer, copolymer, or copolymer microcapsules.
- the polymer or copolymer is dissolved in a miscible mixture of solvent and nonsolvent, at a nonsolvent concentration which is immediately below the concentration which would produce phase separation (i.e., cloud point).
- the liquid core material is added to the solution while agitating to form an emulsion and disperse the material as droplets. Solvent and nonsolvent are vaporized, with the solvent being vaporized at a faster rate, causing the polymer or copolymer to phase separate and migrate towards the surface of the core material droplets.
- phase separated solution is then transferred into an agitated volume of nonsolvent, causing any remaining dissolved polymer or copolymer to precipitate and extracting any residual solvent from the formed membrane.
- the result is a microcapsule composed of polymer or copolymer shell with a core of liquid material.
- a polymer In solvent removal encapsulation, a polymer is typically dissolved in an oil miscible organic solvent and the material to be encapsulated is added to the polymer solution as a suspension or solution in organic solvent. An emulsion is formed by adding this suspension or solution to a vessel of vigorously stirring oil, in which the oil is a nonsolvent for the polymer and the polymer/solvent solution is immiscible in the oil. The organic solvent is removed by diffusion into the oil phase while continuing to stir. Solvent removal results in precipitation of the polymer, forming solid microcapsules containing core material.
- phase separation encapsulation the material to be encapsulated is dispersed in a polymer solution by stirring. While continuing to uniformly suspend the material through stirring, a nonsolvent for the polymer is slowly added to the solution to decrease the polymer's solubility. Depending on the solubility of the polymer in the solvent and nonsolvent, the polymer either precipitates or phase separates into a polymer rich and a polymer poor phase. Under proper conditions, the polymer in the polymer rich phase will migrate to the interface with the continuous phase, encapsulating the core material in a droplet with an outer polymer shell.
- Spontaneous emulsification involves solidifying emulsified liquid polymer droplets by changing temperature, evaporating solvent, or adding chemical cross-linking agents. Physical and chemical properties of the encapsulant and the material to be encapsulated dictates suitable methods of encapsulation. Factors such as hydrophobicity, molecular weight, chemical stability, and thermal stability affect encapsulation.
- Coacervation is a process involving separation of colloidal solutions into two or more immiscible liquid layers (Dowben, R. General Physiology, Harper & Row, New York, 1969, pp. 142-143).
- coacervation compositions comprised of two or more phases and known as coacervates may be produced.
- the ingredients that comprise the two phase coacervate system are present in both phases; however, the colloid rich phase has a greater concentration of the components than the colloid poor phase.
- Low temperature microsphere formation has been described, see, e.g., U.S. Pat. No. 5,019,400.
- the method is a process for preparing microspheres which involves the use of very cold temperatures to freeze polymer-biologically active agent mixtures into polymeric microspheres.
- the polymer is generally dissolved in a solvent together with an active agent that can be either dissolved in the solvent or dispersed in the solvent in the form of microparticles.
- the polymer/active agent mixture is atomized into a vessel containing a liquid non-solvent, alone or frozen and overlayed with a liquefied gas, at a temperature below the freezing point of the polymer/active agent solution.
- the cold liquefied gas or liquid immediately freezes the polymer droplets.
- the solvent in the droplets thaws and is extracted into the non-solvent, resulting in hardened microspheres.
- Phase separation encapsulation generally proceeds more rapidly than the procedures described in the preceding paragraphs.
- a polymer is dissolved in the solvent.
- An agent to be encapsulated then is dissolved or dispersed in that solvent.
- the mixture then is combined with an excess of nonsolvent and is emulsified and stabilized, whereby the polymer solvent no longer is the continuous phase.
- Aggressive emulsification conditions are applied in order to produce microdroplets of the polymer solvent.
- the stable emulsion is introduced into a large volume of nonsolvent to extract the polymer solvent and form microparticles. The size of the microparticles is determined by the size of the microdroplets of polymer solvent.
- PIN phase inversion nanoencapsulation
- a polymer is dissolved in an effective amount of a solvent.
- the agent to be encapsulated is also dissolved or dispersed in the effective amount of the solvent.
- the polymer, the agent and the solvent together form a mixture having a continuous phase, wherein the solvent is the continuous phase.
- the mixture is introduced into an effective amount of a nonsolvent to cause the spontaneous formation of the microencapsulated product, wherein the solvent and the nonsolvent are miscible.
- the conditions can be controlled by one skilled in the art to yield encapsulated material with the desired attributes.
- the average particle size, hydrophobicity, biocompatibility, ratio of core material to encapsulant, thermal stability, and the like can be varied by one skilled in the art.
- the composition comprising the labile compound with a first encapsulant comprises a whole cell biomass
- the cell e.g., a microbial cell
- a labile compound such as a PUFA, a vitamin or other beneficial compound.
- Whole cells include those described above as sources for PUFAs.
- the cellular structure e.g., a cell wall or cell membrane
- biomass can refer to multiple whole cells that, in the aggregate, constitute a biomass.
- a microbial biomass can refer to a biomass that has not been separated from the culture media in which the biomass organism was cultured.
- An example of a culture media is a fermentation broth.
- the biomass is separated from its culture media by a solid/liquid separation prior to treatment by methods of the present invention.
- Typical solid/liquid separation techniques include centrifugation, filtration, and membrane filter pressing (plate and frame filter press with squeezing membranes). This (harvested) biomass usually has a dry matter content varying between 5% and 60%.
- the biomass can be dewatered by any method known in the art, such as, for example, spray drying, fluidized bed drying, lyophilization, freeze drying, tray drying, vacuum tray drying, drum drying, solvent drying, excipient drying, vacuum mixer/reactor drying, drying using spray bed drying, fluidized spray drying, conveyor drying, ultrafiltration, evaporation, osmotic dehydration, freezing, extrusion, absorbent addition or other similar methods, or combinations thereof.
- the drying techniques referenced herein are well known in the art.
- excipient drying refers to the process of atomizing liquids onto a bed of material such as starch
- solvent drying refers to a process where a solvent, miscible with water, is used in excess to replace the water.
- the biomass can optionally be washed in order to reduce extracellular components.
- the fermentation broth can be dried and then reconstituted to a moisture content of any desired level before treatment by any of the methods of the present invention.
- hydrolyzing enzymes can be applied to dried biomass to form a biomass hydrolysate, described elsewhere herein.
- the whole cell is a probiotic organism.
- probiotics are microorganisms that are intended to confer a beneficial health effect when consumed by favorably altering the intestinal microflora balance, inhibiting the growth of harmful bacteria, producing beneficial compositions, promoting good digestion, boosting immune function, and/or increasing resistance to infection.
- Lactobacillus acidophilus is considered to be beneficial because it produces vitamin K, lactase, and anti-microbial substances such as acidolin, acidolphilin, lactocidin, and bacteriocin.
- Probiotics include, for example, lactic acid bacteria, and bifidobacteria.
- Lactic acid bacteria include, for example, Lactococcus lactis, Lactobacillus acidolphilus, Lactobacillus crispatus, Lactobacillus amylovorous, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus rhamnosus, Lactobacillus brevis, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus helveticus, Lactobacillus casei, Lactobacillus delbruckii, Lactobacillus bulgaricus, Lactobacillus plantarum, and Lactobacillus GG.
- Bifidobacteria include, for example, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, and Bifidobacterium longum. Additional probiotic bacteria include, for instance, Streptococcus thermophilus and Leuconostoc mesenteroides. Without intending to be bound by theory, the beneficial effects of these microorganisms can be preserved if encapsulated by a second encapsulant.
- the probiotic microorganism is encapsulated under conditions in which the microorganism retains its beneficial probiotic properties. For example, encapsulation with a second encapsulant can be performed at a temperature lower than the temperature required for inactivation of the microorganism, generally in the range of 90-100° C.
- the composition comprising the labile compound with a first encapsulant comprises an emulsified biomass hydrolysate.
- Such compositions and methods for making the same are described in detail in U.S. Provisional Patent Application Ser. No. 60/680,740, filed on May 12, 2005; U.S. Provisional Patent Application Ser. No. 60/781,430, filed on Mar. 10, 2006; and U.S. patent application Ser. No. 11/433,752, filed on May 12, 2006, all of which are incorporated herein by reference.
- an emulsified biomass hydrolysate is obtained by hydrolyzing a nutrient-containing biomass to produce a hydrolyzed biomass, and emulsifying the hydrolyzed biomass to fonn a stable product.
- the stable product is typically an emulsion or a dry composition resulting from subsequent drying of the emulsion.
- the composition comprising the labile compound with a first encapsulant comprises an oilseed.
- oilseeds can be selected from those generally described above as sources for PUFAs and can include oilseeds from plants that have been genetically modified and plants that have not been genetically modified.
- products of the present invention include a second encapsulant of the first encapsulant.
- the second encapsulant of the first encapsulant is believed to further protect the composition comprising the labile compound to reduce the likelihood of or degree to which the labile compound undergoes a chemical, physical, or biological change or breakdown.
- the second encapsulant can form a continuous coating on the first encapsulant (100% encapsulation) or alternatively, fonn a non-continuous coating (e.g., at a level that provides substantial coverage of the first encapsulant, for example, coverage at 80%, 90%, 95%, or 99%).
- the second encapsulant can be a matrix in which the first encapsulant is entrapped.
- the second encapsulant can be applied by any method known in the art, such as spray drying, fluid bed drying, drum (film) drying, coacervation, interfacial polymerization, fluid bed processing, pan coating, spray gelation, ribbon blending, spinning disk, centrifugal coextrusion, inclusion complexation, emulsion stabilization, spray coating, extrusion, liposome nanoencapsulation, supercritical fluid microencapsulation, suspension polymerization, cold dehydration processes, spray cooling/chilling (prilling), evaporative dispersion processes, and methods that take advantage of differential sohlbility of coatings at varying temperatures.
- a second encapsulant can encapsulate a single discrete particle (i.e., a particle that is a first encapsulant of a composition comprising a labile compound)
- a second encapsulant can alternatively encapsulate a plurality of discrete particles within a single second encapsulant.
- the second encapsulant of the first encapsulant is a prill coating.
- Prilling is a process of encapsulating compounds in a high temperature melt matrix wherein the prilling material goes from solid to liquid above room temperature.
- a prill coating is a wax, oil, fat, or resin, typically having a melting point of about 25-150° C.
- the prill coating can envelop the first encapsulant completely (100% encapusulation), or the prill coating can envelop the first encapsulant at some level less than 100%, but at a level which provides substantial coverage of the first encapsulant, for example, at about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, or about 99%.
- the prill coating is edible. More particularly, the prill coating can comprise, for example, a fatty acid monoglyceride; a fatty acid diglyceride; a fatty acid triglyceride; a free fatty acid (such as stearic acid, palmitic acid, and oleic acid); tallow (such as beef tallow, mutton tallow, and lamb tallow); lard (pork fat); beeswax; lanolin; shell wax; insect wax including Chinese insect wax; vegetable wax, carnauba wax; candelilla wax; bayberry wax; sugar cane wax; mineral wax; paraffin microcrystalline petroleum wax; ozocerite wax; ceresin wax; montan synthetic wax, low molecular weight polyolefin; polyol ether-esters, sorbitol; Fischer-Tropsch process synthetic wax; rosin; balsam; shellac; stearylamide; ethylenebisstearylamide; hydrogenated cast
- the prill coating is hydrogenated cottonseed oil, hydrogenated sunflower oil, hydrogenated safflower oil, hydrogenated soybean oil, hydrogenated corn oil, hydrogenated olive oil, hydrogenated canola oil, hydrogenated linseed oil, or hydrogenated flaxseed oil.
- the prill coating further comprises an additional component.
- the additional component can be, for example, a fat-soluble or fat dispersible antioxidant, oxygen scavenger, colorant or flavor agent.
- a fat-soluble or fat dispersible antioxidant can be, for example, vitamin E, tocopherol, butylhydroxytoluene (BHT), butylhydroxyanisole (BHA), tert-butylhydroquinone (TBHQ), propyl gallate (PG), vitamin C, ascorbyl palmitate, phospholipids, a Maillard reaction product, natural antioxidants (such as spice extracts, e.g., rosemary or oregano extracts, and seed extracts, e.g., grapeseed extracts or pomegranate extract), and combinations thereof.
- natural antioxidants such as spice extracts, e.g., rosemary or oregano extracts, and seed extracts, e.g., grapeseed extracts or pomegranate extract
- the Maillard reaction product can be added as an antioxidant in addition to Maillard reaction products described elsewhere.
- Such an oxygen scavenger can be, for example, ascorbic acid, isoascorbic acid, erythorbic acid, or mixtures of salts thereof.
- the colorant component is selected from the group consisting of water soluble natural or artificial dyes that include FD&C dyes (food, drug and cosmetic use dyes) of blue, green, orange, red, yellow and violet; iron oxide dyes; ultramarine pigments of blue, pink, red and violet; and equivalents thereof.
- FD&C dyes food, drug and cosmetic use dyes
- flavor agents include flavor oils such as peppermint oil, spearmint oil, cinnamon oil, oil of wintergreen, nut oil, licorice, vanilla, citrus oils, fruit essences and mixtures thereof.
- Citrus oils and fruit essences include apple, apricot, banana, blueberry, cherry, coconut, grape, grapefruit, lemon, lime, orange, pear, peaches, pineapple, plum, raspberry, strawberry, and mixtures thereof.
- flavor agents include oleoresin extracts of spices includes, for example oleoresin extracts of tarragon, thyme, sage, rosemary, oregano, nutmeg, basil, bay, cardamom flavor, celery, cilantro, cinnamon, clove, coriander, cumin, fennel, garlic, ginger, mace, marjoram, capsicum, black pepper, white pepper, annatto, paprika, turmeric, cajun, and mixtures thereof.
- oleoresin extracts of spices includes, for example oleoresin extracts of tarragon, thyme, sage, rosemary, oregano, nutmeg, basil, bay, cardamom flavor, celery, cilantro, cinnamon, clove, coriander, cumin, fennel, garlic, ginger, mace, marjoram, capsicum, black pepper, white pepper, annatto, paprika, turmeric, cajun, and mixtures thereof.
- the prill coating is applied by a prilling method with the resultant product being a prill or bead.
- Prilling is also known in the art as spray cooling, spray chilling, and/or matrix encapsulation. Prilling is similar to spray drying in that a core material, in the present case, a first encapsulant of a composition comprising a labile compound, is dispersed in a liquefied coating or wall material and atomized. Unlike spray drying, there is no water present to be evaporated. The core material and the second encapsulant can be atomized into cooled or chilled air, which causes the wall to solidify around the core. In spray chilling, the prill coating typically has a melting point between about 32° C.
- the prill coating typically has a melting point of between about 45° C. and about 122° C.
- the prill coating is applied by a modified prilling method.
- a modified prilling method for example, can be a spinning disk process or centrifugal coextrusion process.
- the product having a prill coating is in a form that results in a free-flowing powder.
- the prill coating is applied so as to form a product into configurations other than powders, such as chips or flakes.
- the equipment converts the liquid prill coating material into a solid by cooling it while it is applied to a first encapsulated product.
- the prill coating and first encapsulant of a composition comprising a labile compound are cooled as the mixture passes through rollers and is formed into a flat sheet, which can then be processed into chips or flakes.
- the mixture can be extruded through dies to form shapes or through blades to be cut into ribbons.
- the second encapsulant of the first encapsulant is a fluid bed coating.
- Application of a fluid bed coating is well suited to uniformly coat or encapsulate individual particulate materials.
- the apparatus for applying a fluid bed coating is typically characterized by the location of a spray nozzle at the bottom of a fluidized bed of solid particles, and the particles are suspended in a fluidizing air stream that is designed to induce cyclic flow of the particles past the spray nozzle.
- the nozzle sprays an atomized flow of coating solution, suspension, or other coating material.
- the atomized coating material collides with the particles as they are carried away from the nozzle.
- the temperature of the fluidizing air is set to appropriately solidify the coating material shortly after colliding with the particles.
- Suitable coating materials include the materials identified above as materials for prill coatings.
- hot-melt coatings are a solid fat (at room temperature) that has been melted and sprayed on to a particle (i.e., a first encapsulant) where it solidifies.
- a benefit of using hot-melt coatings is that they have no solvent to evaporate and are insoluble in water, they are also low cost and easily obtainable.
- Typical coating volume for hot-melt application to a first encapsulant is 50% (one half hot-melt coating and one half first encapsulant and core material).
- Additional encapsulants for example, a third encapsulant, a fourth encapsulant, a fifth encapsulant, and so on, are also contemplated in the present invention. Additional encapsulants can be applied by methods described herein, and can provide additional desirable properties to the products. For example, the additional encapsulants can further enhance the shelf life of the products, or modify the release properties of the product to provide for controlled release or delayed release of the labile compound.
- the product further comprises a Maillard reaction product (MRP).
- MRP Maillard reaction product
- a reducing sugar is a sugar with a ketone or an aldehyde functional group, which allows the sugar to act as a reducing agent in the Maillard reaction. This reaction occurs in most foods on heating. Maillard reaction chemistry can affect desirable flavors and color of a wide range of foods and beverages. While not being bound by theory, it is believed that formation of MRPs in the products of the invention produces aromas and flavors that are desirable for inclusion in food products or other products that are consumed. MRPs can also possess antioxidant activity, and without being bound by theory, it is believed that this property of the MRPs imparts increased stability and shelf life to the products of the present invention.
- the Maillard reactions are well-known and from the detailed specification herein, temperature and time required to carry the reaction to the desired extent can be determined.
- the MRP can be included in the products of the present invention in a number of ways.
- the MRP is a product of a reducing sugar and an amino acid source that is a protein.
- Proteins that can be used to produce an MRP include casein, whey solids, whey protein isolate, soy protein, skim milk powder, hydrolyzed casein, hydrolyzed whey protein, hydrolyzed soy protein, non-fat milk solids, gelatin, zein, albumin, and the like.
- amino acids can be provided directly or by in situ formation, such as by acid, alkaline or enzymatic hydrolysis.
- the reducing sugar can include sugars, such as fructose, glucose, glyceraldehyde, lactose, arabinose, and maltose.
- the term reducing sugar also includes complex sources of reducing sugars.
- suitable complex sources include corn syrup solids and modified starches such as chemically modified starches and hydrolysed starches or dextrins, such as maltodextrin. Hydrolysed starches (dextrins) are used in some embodiments.
- the reducing sugar is formed in situ from, for example, a compound that is not itself a reducing sugar, but comprises reducing sugars.
- starch is not a reducing sugar, but is a polymer of glucose, which is a reducing sugar. Hydrolysis of starch, by chemical or enzymatic means, yields glucose. This hydrolysis can take place in situ, to provide the reducing sugar glucose.
- the reducing sugars and protein used to form MRPs in various embodiments of the present invention can naturally occur in the first encapsulant of the composition or the second encapsulant.
- the first encapsulant being a microbial biomass hydrolysate emulsion
- the reducing sugars and proteins can be present without being added.
- various embodiments of the invention contemplate the addition of some or all of the reducing sugar and protein.
- an MRP is formed by contacting the first encapsulant with the second encapsulant.
- a product comprising a composition comprising a labile compound, a first encapsulant of the composition, and a second encapsulant of the first encapsulant, wherein the product further comprises an MRP formed by contacting the first encapsulant with the second encapsulant.
- the first encapsulant and second encapsulants are brought into contact, they are done so in the presence of reducing sugars and protein under suitable temperature and time conditions to form MRPs.
- the second encapsulant when the second encapsulant is a prill coating, contacting the first encapsulant with the liquefied prill coating at elevated temperature in the presence of reducing sugars and proteins can promote the formation of MRPs.
- the temperature of such a reaction ranges from about 20° C. to about 150° C. with from about 80° C. to about 110° C. being preferred.
- the time of the reaction ranges from about 1 minute to about several hours, depending on the temperature. At the preferred higher temperature range, the time of reaction is preferably about 1 minute to about 20 minutes.
- Reference to “time of reaction” in this paragraph refers to the time that the first encapsulant is in contact with the liquefied prill coating before cooling to solidify the coating.
- the Maillard reaction product is formed in a non-aqueous environment.
- the invention provides a product comprising a composition comprising a labile compound, a first encapsulant of the composition, and a second encapsulant of the first encapsulant, wherein the product further comprises a Maillard reaction product formed in a non-aqueous environment.
- the second encapsulant is a prill coating
- contacting the first encapsulant with the liquefied prill coating at elevated temperature in the presence of reducing sugars and proteins can promote the formation of MRPs in the environment of the liquefied prill coating, i.e., a non-aqueous environment.
- the reaction is analogous to browning in oil.
- Water is produced as a byproduct of the Maillard reaction, and therefore the presence of water is inhibitory for the formation of MRPs.
- reference to a non-aqueous environment encompasses an environment comprising small amounts of water, such as that produced by the Maillard reaction.
- the first encapsulated product comprises the amino acid source and the reducing sugar source. In some embodiments, the first encapsulated product comprises the amino acid source and the second encapsulant comprises the reducing sugar source. In other embodiments, the first encapsulated product comprises the reducing sugar source and the second encapsulant comprises the amino acid source. In still other embodiments, the second encapsulant comprises the reducing sugar and the amino acid source. In other embodiments, the amino acid source and/or the reducing sugar source can be present in both the first encapsulated product and the second encapsulant.
- the second encapsulant comprises an MRP.
- the invention provides a product comprising a composition comprising a labile compound, a first encapsulant of the composition, a second encapsulant of the first encapsulant, wherein the second encapsulant further comprises a Maillard reaction product.
- the MRP can be produced separately and introduced into the second encapsulant prior to encapsulation of the first encapsulant.
- MRPs will be formed throughout the second encapsulant.
- the MRPs will be dispersed throughout the second encapsulant.
- MRPs will occur, not just at the interface between the first and second encapsulants, but in the outer portions of the second encapsulant away from the first encapsulant.
- the MRPs will occur in the outer 75%, 50% or 25% of the second encapsulant.
- the products of the present invention can be is characterized in general by parameters such as particle size and distribution, particle geometry, active contents and distribution, release mechanism, arid storage stability.
- the product in some embodiments in which the product is in a powder fonn, the product has a particle size of between about 10 ⁇ m and about 3000 ⁇ m, and in another embodiment between about 40 ⁇ m and 300 ⁇ m.
- the products are insoluble in cold to warm water, and in some embodiments, have a water solubility of less than about 0.1 mg/ml.
- the solubility of the product in a given environment will depend on the melting point of the second encapsulant.
- One skilled in the art can select an appropriate second encapsulant for the anticipated use and environment for the product.
- the products of the invention are generally physically stable.
- the product is physically stable for at least about 30 days, at least about 60 days, at least about 90 days, at least about 120 days, at least about one year, at least about three years, or at least about five years.
- Physical stability refers to the ability of a product to maintain its physical appearance over time. For example, the structure of a product, with the first encapsulant of the composition and the second encapsulant of the first encapsulant, is substantially maintained without, for example, the composition migrating through the first encapsulant to the second encapsulant.
- the products the invention are oxidatively stable.
- oxidative stability refers to the lack of significant oxidation in the labile compound over a period of time.
- Oxidative stability of fats and oils can be determined by one skilled in the art.
- peroxide values indicate the amount of peroxides present in the fat and are generally expressed in milli-equivalent oxygen per kg fat or oil.
- anisidine values measure carbonyl (aldehydes and ketones) components which are formed during deterioration of oils. Anisidine values can be determined as described in IUPAC, Standard Methods for the Analysis of Oils, Fats and Derivatives, 6th Ed. (1979), Pergamon Press, Oxford, Method 2,504, page 143.
- the products of the invention in some embodiments, have a peroxide value of less than about 2, or less than about 1. In other embodiments, products of the invention have an anisidine value of less than about 1. In some embodiments, the product is oxidatively stable for at least about 30 days, at least about 60 days, at least about 90 days, at least about 120 days, at least about one year, at least about three years, or at least about five years.
- the products have desirable aromas or flavors.
- a desirable aroma or flavor is due to the presence of Maillard reaction products.
- a desirable aroma or flavor, or lack of an undesirable aroma or flavor is imparted to the product by the physical and oxidative stability of the product.
- the presence of desirable aromas and flavors can be evaluated by one skilled in the art. For example, the room-odor characteristics of cooking oils can be reproducibly characterized by trained test panels in room-odor tests (Mounts, J. Am. Oil Chem. Soc. 56:659-663, 1979).
- a standardized technique for the sensory evaluation of edible vegetable oils is presented in AOCS' Recommended Practice Cg 2-83 for the Flavor Evaluation of Vegetable Oils (Methods and Standard Practices of the AOCS, 4th Edition (1989)).
- the technique encompasses standard sample preparation and presentation, as well as reference standards and method for scoring oils.
- Panelists can be asked to rank the products on a Hedonic scale.
- Such a scale can be a scale of 1-10 used for the overall odor and flavor in which 10 is assigned to “complete blandness”, and 1 to “strong obnoxiousness”. The higher score will indicate better product in terms of aroma and flavor.
- products of the present invention will have a score of at least about 5, at least about 6, at least about 7, at least about 8, at least about 9 or about 10 in such a test.
- Such evaluations can be conducted at various time frames, such as upon production of the product, at least about 60 days after production, at least about 90 days after production, at least about 120 days after production, at least about one year after production, at least about three years after production, or at least about five years after production.
- the amount of labile compound in the products of the invention will vary depending on the type of compound, the encapsulation materials used, and the methods used for forming the product.
- the product comprises labile compound in an amount of at least about 1 to 20 weight percent, in 1% increments and up to about 40 to 80 weight percent, in 1% increments, for example, between about 1 weight percent and about 80 weight percent, between about 5 weight percent and about 70 weight percent, between about 10 weight percent and about 60 weight percent, or between about 15 weight percent and about 50 weight percent.
- the present invention also provides methods for preparing the products described herein. Some of these methods have been described above.
- the invention provides a method for preparing a product comprising encapsulating a first encapsulated product in the presence of an amino acid source and a reducing sugar to form a second encapsulated product.
- a first encapsulated product In the process of encapsulating a first encapsulated product, Maillard reaction products are formed.
- the first encapsulated product comprises an encapsulant of a labile compound.
- this method further includes handling the labile compound under conditions that reduce oxidative degradation prior to encapsulation. Such handling can include, for example, maintaining the product in an inert atmosphere, the addition of antioxidants to the labile compound, and so forth.
- this method further comprises processing the second encapsulated product into a particulate form.
- the particulate form can be selected from the group consisting of a bead, a chip, and a flake.
- the first encapsulated product is formed by a method comprising emulsifying an aqueous dispersion of a polyunsaturated fatty acid, protein and reducing sugar to form an emulsion. This method further includes drying the emulsion to form the first encapsulated product.
- encapsulating the first encapsulated product comprises contacting the first encapsulated product with a prilling material, spraying the mixture of the first encapsulated product with the prilling material into droplets, and cooling the droplets below the melting point of the prilling material to form the second encapsulated product.
- the prilling material has a melting point in the range of about 32° C. to about 122° C.
- the step of contacting the first encapsulated product with the prilling material is conducted at a temperature above about 85° C.
- the step of contacting the first encapsulated product with the prilling material is conducted for between about 1 minute and about 15 minutes.
- the prilling material is hydrogenated vegetable oil, and the step of contacting the first encapsulated product with the prilling material is conducted for between about 1 minute and about 15 minutes, between 80° C. and 100° C.
- the first encapsulated product comprises about 25 wt % to about 80 wt % labile compound; about 5 wt % to about 25 wt % of an amino acid source; and about 15 wt % to about 70 wt % of a reducing sugar.
- the products of the present invention can be incorporated into nutritional products (including food products, food supplements, feed products, feed supplements, and nutraceutical products), cosmetic products, pharmaceutical products, and industrial products.
- Products can be in the form of chewable tablets, quick dissolve tablets, effervescent tablets, reconstitutable powders, elixirs, liquids, solutions, suspensions, emulsions, tablets, multi-layer tablets, bi-layer tablets, capsules, soft gelatin capsules, hard gelatin capsules, caplets, lozenges, chewable lozenges, beads, powders, granules, particles, dispersible granules, dietary supplements, genetically engineered designer foods, herbal products, and processed foods.
- a nutritional product may be used directly as a food product, food supplement, feed product, feed supplement or as an ingredient in any of the foregoing.
- Food products can be liquid food products or solid food products.
- Liquid food products include, for example, infant formula, liquid meals, liquid eggs, multivitamin syrups, meal replacers, medicinal foods, soups and syrups, and beverages.
- a beverage is any one of various liquids for drinking. Beverages include, for example, energy drinks, fruit juices, milk, and milk products.
- Solid food products include, for example, baby food, yogurt, cheese, cereal, powdered mixes, baked goods, including, for example, such items as cakes, cheesecakes, pies, cupcakes, cookies, bars, breads, rolls, biscuits, muffins, pastries, scones, and croutons, food bars including energy bars, and processed meats.
- doughs, batters, ice creams; frozen desserts; frozen yogurts; waffle mixes; salad dressings; and replacement egg mixes baked goods such as cookies, crackers, sweet goods, snack cakes, pies, granola/snack bars, and toaster pastries; salted snacks such as potato chips, corn chips, tortilla chips, extruded snacks, popcorn, pretzels, potato crisps, and nuts; specialty snacks such as dips, dried fruit snacks, meat snacks, pork rinds, health food bars and rice/corn cakes; and confectionary snacks such as candy.
- the product can be processed into a particulate form.
- the particulate form can be selected from the group consisting of a bead, a chip, and a flake.
- Feed or feed supplements can be prepared for any companion animal or pet or for any animal whose meat or products are consumed by humans.
- the term “animal” means any organism belonging to the kingdom Animalia and includes, without limitation, any animal from which poultry meat, seafood, beef, pork or lamb is derived. Seafood is derived from, without limitation, fish, shrimp and shellfish.
- Animal product includes any product other than meat derived from such animals, including, without limitation, eggs, milk or other products. When fed to such animals, nutrients such as LC PUFAs can be incorporated into the flesh, milk, eggs or other products of such animals to increase their content of these nutrients.
- a cosmetic product is a product that is applied to the skin and can function either to improve the appearance of the skin or to provide some dermatological benefit to the skin.
- An industrial product is a product such as a raw material for manufacturing paints, wood products, textiles, adhesives, sealants, lubricants, leather, rope, paper pulp, plastics, fuels, oil, rubber working fluids, or metal working fluids.
- This example illustrates the production of a product of the present invention in which the composition comprising a labile compound is an algal oil and the first encapsulant is formed by spray drying.
- the second encapsulant is a prill coating of hydrogenated canola wax.
- Spray dried particles of algal oil in a sugar-protein matrix prepared in accordance with the process generally described in EP 1 616 486, entitled Powdered Compositions Containing an Edible Oil and Their Use in Food Products, which is incorporated herein by reference, with a mean size of 78 ⁇ m were prilled in hydrogenated canola wax (Stable Flake—CN, Cargill). This material was prilled at a concentration of 33% (one-third by weight spray dried particles with two-thirds by weight canola oil) with good results. The resulting product had a mean particle size of 157 microns.
- first encapsulant of the composition comprising the labile compound is a biomass hydrolysate.
- the second encapsulant is a prill coating of hydrogenated canola wax.
- the resultant solution was atomized using compressed air at 154° C. and 45 psi into a prill tower using ambient air as the cooling air.
- the powder was collected and analyzed for particle size, solubility and sensory profile.
- the particle size of the original hydrolysate power was 70.5 micron.
- the average particle size of the prills was 82.9 micron.
- the powder was found to be mostly water insoluble with improved, pleasant aroma and acceptable sensory profile.
- the product of the present invention is one in which composition comprising a labile compound is an algal oil and the first encapsulant is formed by reacting a solution comprising a protein, soy protein isolate, and a reducing sugar at a starting pH of 10 to achieve a degree of protein hydrolysis of between about 1% and about 15%, and combining the reacted solution with the algal oil, such that the reacted solution forms an encapsulant on the algal oil, and spray drying resulting mixture.
- This method is described in detail in U.S. provisional patent application Ser. No. 60/945,040, filed Jun. 19, 2007, which is herein incorporated by reference in its entirety.
- the second encapsulant is a prill coating of hydrogenated soy fat.
- the algal oil with a first encapsulant and no second encapsulant was used.
- Results are expressed as induction period. Induction period for the sample was defined as the time when an average sensory score of 3.0 or greater first appeared (based on a 5 point scale). Head space induction periods are defined as the time there is a sharp increase (inflection point) in the concentration of volatiles hexanal and propanal. Results are shown in FIG. 1 . Sensory analysis indicates prilling of core material results in nearly an 8-fold increase in induction period (3 wks vs.
Abstract
Description
- This application claims the benefit of priority under 35 U.S.C. §119(e) of U.S. Provisional Application Ser. No. 60/805,950, filed Jun. 22, 2006 and U.S. Provisional Application Ser. No. 60/945,040 filed Jun. 19, 2007. The disclosure of each of these applications is incorporated by reference herein in its entirety.
- The invention relates to encapsulated labile compounds, including polyunsaturated fatty acids, and methods of making the same.
- Labile compounds and compositions, such as polyunsaturated fatty acids (PUFAs), vitamins, minerals, antioxidants, hormones, amino acids, proteins, carbohydrates, coenzymes, and flavor agents, sensitive to any number of factors, can lose biological or other desired activity when unprotected. In addition, products (for example, decomposition products, degradation products, and oxidation products) that result from the chemical, physical, or biological change or breakdown of labile compounds and compositions, could lack the desired biological function and/or possess unwanted characteristics, such as having off-flavors, undesirable odors, irritation promoting activity and the like. There is often a need to introduce labile compounds and compositions, which are susceptible to chemical, physical, or biological change or breakdown, into pharmaceutical, nutritional, including nutraceutical, and industrial products. In such instances, protection of such compounds and compositions is desirable. With regard to PUFAs in particular, it is desirable to protect such lipids in food products from oxygen, trace metals and other substances which attack the double bonds of the PUFAs. Such protection reduces the likelihood of organoleptic problems, i.e., problems, relating to the senses (taste, color, odor, feel), such as off-flavors and undesirable odors, and other problems, such as loss of physiological activity, for instance. Such protection could potentially increase the shelf life of products containing them.
- Encapsulating unstable compounds can protect them from undesirable chemical, physical, or biological change or breakdown while retaining their efficacy, such as biological or physiological efficacy. Microcapsules can exist in powdered form and comprise roughly spherical particles that contain an encapsulated (entrapped) substance. The particle usually has some type of shell, often a polymeric shell, such as a polypeptide or polysaccharide shell, and the encapsulated active product is located within the shell. Microencapsulation of a liquid, such as an oil, allows the formation of a particle that presents a dry outer surface with an entrained oil. Often the particles are a free-flowing powder. Microencapsulation therefore effectively enables the conversion of liquids to powders. Numerous techniques for microencapsulation are known depending on the nature of the encapsulated substance and on the type of shell material used. Methods typically involve solidifying emulsified liquid droplets by changing temperature, evaporating solvent, or adding chemical cross-linking agents. Such methods include, for example, spray drying, interfacial polymerization, hot melt encapsulation, phase separation encapsulation (solvent removal and solvent evaporation), spontaneous emulsion, solvent evaporation microencapsulation, solvent removal microencapsulation, coacervation, and low temperature microsphere formation and phase inversion nanoencapsulation (PIN). Microencapsulation is suitable for drugs, vitamins and food supplements since this process is adaptable by varying the encapsulation ingredients and conditions.
- There is a particular need to provide microencapsulated forms of fats or oils, such as vegetable and marine oils, which contain PUFAs. Such microencapsulated forms would benefit from the properties of digestibility, stability, resistance to chemical, physical, or biological change or breakdown. Microencapsulated oils could conveniently be provided as a free flowing powdered form. Such a powder can be readily mixed with other dry or liquid components to form a useful product.
- The ability to microencapsulate, however, can be limited by factors due to the nature of the microencapsulation process or the compound or composition to be encapsulated. Such factors could include pH, temperature, uniformity, viscosity, hydrophobicity, molecular weight, and the like. Additionally, a given microencapsulation process may have inherent limitations. For example, in microencapsulation techniques in which heat is used for drying, low-boiling point aromatics can be lost during the drying process. Additionally, the core may adhere to the surface of the encapsulation material, presenting a potential for increased oxidation and changes in the flavor balance of the finished product. In some cases, storage conditions must be carefully controlled to avoid an increase in the water activity and therefore the stability of the capsule and retention of volatiles within the capsule. During spray drying microencapsulation, the feed inlet temperature may not be high enough and result in incomplete drying and sticking in the drying chamber or clump formation in storage. Particulate inconsistencies may also occur under some process conditions. At temperatures that are too low, the particles may balloon and cracks can form in the surface of the particles. This may cause loss of volatile compounds and compromise the quality of the final product. Yet another drawback is that the coatings produced are often water-soluble and temperature sensitive. The present inventors have recognized the foregoing problems and that there is a need, therefore, to provide additional processes for encapsulation of compounds and compositions susceptible to chemical, physical, or biological change or breakdown.
- The present invention is directed to products comprising labile compounds, such as polyunsaturated fatty acids, and having first and second encapsulants, as well as methods of making the same.
- In one embodiment, the invention provides a product comprising a composition comprising a labile compound; a first encapsulant of the composition; and a second encapsulant of the first encapsulant, wherein the second encapsulant is a prill coating, wherein the product further comprises a Maillard reaction product.
- The invention also provides a product comprising a composition comprising a labile compound; a first encapsulant of the composition; and a second encapsulant of the first encapsulant, wherein the product further comprises a Maillard reaction product formed by contacting the first encapsulant with the second encapsulant.
- The invention further provides a product comprising a composition comprising a labile compound; a first encapsulant of the composition; and a second encapsulant of the first encapsulant, wherein the second encapsulant further comprises a Maillard reaction product.
- The invention also provides a product comprising a composition comprising a labile compound; a first encapsulant of the composition; and a second encapsulant of the first encapsulant, wherein the product further comprises a Maillard reaction product formed in a non-aqueous environment.
- The labile compound includes polyunsaturated fatty acid, a vitamin, a mineral, an antioxidant, a hormone, an amino acid, a protein, a carbohydrate, a coenzyme, a flavor agent, and mixtures of the foregoing.
- The invention also provides a product comprising a composition comprising a labile compound selected from the group consisting of a polyunsaturated fatty acid, a vitamin, a mineral, an antioxidant, a hormone, an amino acid, a protein, a carbohydrate, a coenzyme, and mixtures thereof; a first encapsulant of the composition; and a prill coating on the first encapsulant.
- In some embodiments, the labile compound comprises a polyunsaturated fatty acid from a source selected from the group consisting of a plant, an oilseed, a microorganism, an animal, and mixtures of the foregoing. In some embodiments, the microorganism includes algae, bacteria, fungi and protists.
- In some embodiments, the source is selected from the group consisting of plant and oilseed selected from the group consisting of soybean, corn, safflower, sunflower, canola, flax, peanut, mustard, rapeseed, chickpea, cotton, lentil, white clover, olive, palm, borage, evening primrose, linseed and tobacco and mixtures thereof.
- In some embodiments, the source includes a genetically modified plant, a genetically modified oilseed, and a genetically modified microorganism, wherein the genetic modification comprises the introduction of polyketide synthase genes.
- In other embodiments, the microorganism includes Thraustochytriales, dinoflagellates, and Mortierella. In still other embodiments, the microorganism includes Schizochytrium, Thraustochytrium or a dinoflagellate of the genus Crypthecodinium.
- In some embodiments, the animal includes an aquatic animal.
- In some embodiments, the labile compound comprises a polyunsaturated fatty acid having a chain length of at least 18 carbons. In other embodiments, the labile compound comprises a polyunsaturated fatty acid including docosahexaenoic acid, omega-3 docosapentaenoic acid, omega-6 docosapentaenoic acid, arachidonic acid, eicosapentaneoic acid, stearidonic acid, linolenic acid, alpha linolenic acid (ALA), gamma linolenic acid (GLA), conjugated linolenic acid (CLA) and mixtures thereof.
- In other embodiments, the labile compound comprises a vitamin selected from the group consisting of Vitamin A, Vitamin D, Vitamin E, Vitamin K, Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B6, Vitamin C, Folic Acid, Vitamin B-12, Biotin, Vitamin B5 and mixtures thereof.
- In other embodiments, the labile compound comprises a mineral selected from the group consisting of calcium, iron, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum and mixtures thereof.
- In still other embodiments, the labile compound comprises an antioxidant selected from the group consisting of lycopene, lutein, zeaxanthin, alpha-lipoic acid, coenzymeQ, beta-carotene and mixtures thereof.
- In further embodiments, the labile compound comprises an amino acid selected from the group consisting of arginine, aspartic acid, carnitine, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, SAM-e and mixtures thereof.
- In some embodiments in which the labile compound is a flavor agent, the flavor agent comprises a flavor oil, oleoresin or mixtures thereof.
- In some embodiments, the first encapsulant of the composition comprising the labile compound includes a whole cell, a biomass hydrolysate, an oilseed and an encapsulated isolated labile compound.
- In other embodiments, the first encapsulant of the composition comprising the labile compound is a whole cell or a biomass hydrolysate derived from microorganisms. The microorganism includes Lactococcus lactis, Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus amylovorous, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus rhamnosus, Lactobacillus brevis, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus helveticus, Lactobacillus casei, Lactobacillus delbruckii, Lactobacillus bulgaricus, Lactobacillus plantarum, Lactobacillus GG, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacteriun infantis, Bifidobacterium longum, Streptococcus thermophilus and Leuconostoc mesenteroides.
- In some embodiments, the first encapsulant of the composition comprising the labile compound is a dried whole cell. In some embodiments, the dried whole cell is a spray-dried whole cell.
- In some embodiments, the first encapsulant is prepared by a method is selected from the group consisting of fluid bed drying, drum (film) drying, coacervation, interfacial polymerization, fluid bed processing, pan coating, spray gelation, ribbon blending, spinning disk, centrifugal coextrusion, inclusion complexation, emulsion stabilization, spray coating, extrusion, liposome nanoencapsulation, supercritical fluid microencapsulation, suspension polymerization, cold dehydration processes, spray chilling (prilling), and evaporative dispersion processes.
- In some embodiments, the prill coating is selected from the group consisting of a fatty acid monoglyceride; a fatty acid diglyceride; a fatty acid triglyceride; a free fatty acid; tallow; lard; beeswax; lanolin; shell wax; insect wax; vegetable wax, camauba wax; candelilla wax; bayberry wax; sugar cane wax; mineral wax; paraffin microcrystalline petroleum wax; ozocerite wax; ceresin wax; montan synthetic wax, low molecular weight polyolefin; polyol ether-esters, sorbitol; Fischer.-Tropsch process synthetic wax; rosin; balsam; shellac; stearylamide; ethylenebisstearylamide; hydrogenated castor oil; esters of pentaerythritol; mono and tetra esters of stearic acid; vegetable oil; a hydrogenated vegetable oil; and mixtures and derivatives of the foregoing.
- In certain embodiments, the prill coating is a free fatty acid selected from the group consisting of stearic acid, palmitic acid, and oleic acid.
- In embodiments in which the prill coating is tallow, the tallow includes sbeef tallow, mutton tallow, pork tallow, and lamb tallow. In embodiments in which the prill coating is hydrogenated vegetable oil, the hydrogenated vegetable oil includes hydrogenated cottonseed oil, hydrogenated sunflower oil, hydrogenated safflower oil, hydrogenated soybean oil, hydrogenated corn oil, hydrogenated olive oil, hydrogenated canola oil, hydrogenated linseed oil, hydrogenated flaxseed oil.
- In some embodiments, the prill coating further comprises a fat-soluble or fat dispersible oxygen scavenger, or a fat-soluble or fat dispersible antioxidant.
- In some embodiments, the prill coating further comprises a colorant.
- In some embodiments, the Maillard reaction product includes a reaction product of a reducing sugar and a protein selected from the group consisting of casein, whey solids, whey protein isolate, soy protein, skim milk powder, hydrolyzed casein, hydrolyzed whey protein, hydrolyzed soy protein, non-fat milk solids, gelatin, zein, and albumin.
- In some embodiments, the Maillard reaction product includes a reaction product of a protein and a reducing sugar selected from the group consisting of fructose, glucose, glyceraldehyde, lactose, arabinose, maltodextrin, corn syrup solids and maltose.
- The invention also provides a product selected from the group consisting of a food product, a cosmetic product, a phannaceutical product, a nutraceutical product, and an industrial product, in which the product comprises a product comprising a composition comprising a labile compound; a first encapsulant of the composition; and a second encapsulant of the first encapsulant, wherein the second encapsulant is a prill coating, wherein the product further comprises a Maillard reaction product.
- In some embodiments, the food product includes liquid food products or solid food products. Liquid food products include beverages, infant formula, liquid meals, liquid eggs, milk products, and multivitamin syrups. Beverages include energy drinks, fruit juices, and milk. Solid food products include baby food, yogurt, cheese, cereal, powdered mixes, baked goods, food bars, and processed meats.
- In some embodiments, the product is insoluble in water. In other embodiments the product is physically stable for at least about 30 days, or oxidatively stable for at least about 30 days.
- In other embodiments, the Maillard reaction product provides a desirable flavor to the product, a desirable aroma to the product, or antioxidant protection to the product.
- In some embodiments, the Maillard reaction product is present in the outer 75% of the second encapsulant.
- In some embodiments, the product has a particle size of between about 10 μm and about 3000 μm.
- In further embodiments, the product comprises labile compound in an amount between about 1 weight percent and about 50 weight percent.
- In still further embodiments, the product is in a form selected from the group consisting of a free-flowing powder, a bead, a chip, and a flake.
- The invention also provides a method for preparing a product comprising encapsulating a first encapsulated product in the presence of an amino acid source and a reducing sugar to form a second encapsulated product, whereby Maillard reaction products are formed, and wherein the first encapsulated product comprises an encapsulant of a labile compound.
- In some embodiments, the method further comprises handling the labile compound under conditions that reduce oxidative degradation prior to encapsulation.
- In some embodiments of the method, the first encapsulated product comprises the amino acid source and the reducing sugar.
- In other embodiments, the method further comprising processing the second encapsulated product into a particulate form. The processing includes fluid bed drying, drum (film) drying, coacervation, interfacial polymerization, fluid bed processing, pan coating, spray gelation, ribbon blending, spinning disk, centrifugal coextrusion, inclusion complexation, emulsion stabilization, spray coating, extrusion, liposome nanoencapsulation, supercritical fluid microencapsulation, suspension polymerization, cold dehydration processes, spray chilling (prilling), and evaporative dispersion processes.
- In further embodiments, the step of encapsulating the first encapsulated product is conducted at a temperature above about 85° C.
- In some embodiments, the step of encapsulating the first encapsulated product is conducted for between about 1 minute and about 15 minutes.
- In other embodiments, the first encapsulated product is formed by a method comprising emulsifying an aqueous dispersion of a polyunsaturated fatty acid, protein and reducing sugar to form an emulsion; and drying the emulsion to form the first encapsulated product.
- In further embodiments, the encapsulating the first encapsulated product comprises contacting the first encapsulated product with a prilling material, spraying the mixture of the first encapsulated product with the prilling material into droplets, and cooling the droplets below the melting point of the prilling material to form the second encapsulated product. In some embodiments, the prilling material has a melting point in the range of about 32° C. to about 122° C.
- In other embodiments, the step of contacting the first encapsulated product with the prilling material is conducted at a temperature above about 85° C.
- In still other embodiments, the step of contacting the first encapsulated product with the prilling material is conducted for between about 1 minute and about 15 minutes.
- In further embodiments, the prilling material is hydrogenated vegetable oil, and the step of contacting the first encapsulated product with the prilling material is conducted for between about 1 minute and about 15 minutes, between 80° C. and 100° C.
- In some embodiments, the first encapsulated product comprises about 25 wt % to about 80 wt % labile compound; about 5 wt % to about 25 wt % of an amino acid source; and about 15 wt % to about 70 wt % of a reducing sugar.
- In other embodiments, the second encapsulated product is in particulate form and wherein the particulates comprise more than one coated encapsulated product per particulate.
-
FIG. 1 shows the improvement in the induction period for a product of the invention (dark grey bars) when compared to a singly encapsulated product (light grey bars). - The present invention provides encapsulated labile compounds and related methods for their preparation. In various embodiments, the invention provides a product comprising a composition comprising a labile compound, a first encapsulant of the composition, and a second encapsulant of the first encapsulant, and in some embodiments, the second encapsulant can be a prill coating. In some embodiments, the product further comprises a Maillard reaction product (MRP). As used herein, the term “a” or “an” refers to one or more of that entity; for example, a PUFA refers to one or more PUFAs or at least one PUFA. As such, the terms “a” (or “an”), “one or more” and “at least one” can be used interchangeably herein. It is also to be noted that the terms “comprising”, “including”, and “having” can be used interchangeably.
- In one embodiment, the invention is directed to a product that includes a composition comprising a labile compound with a first encapsulant of the composition and a prill coating on the first encapsulant. In this embodiment, the product further comprises a Maillard reaction product. Reference to a prill coating or a second encapsulant being “on the first encapsulant” refers to the prill coating or second encapsulant coating or partially coating the first encapsulant and the composition having a labile compound. It will be recognized that the prill coating or the second encapsulant can either contact the first encapsulant directly or can contact the first encapsulant through one or more intervening layers of other materials.
- In one embodiment, the invention is directed to a product that includes a composition comprising a labile compound selected from the group consisting of a polyunsaturated fatty acid, a vitamin, a mineral, an antioxidant, a hormone, an amino acid, a protein, a carbohydrate, a coenzyme, and mixtures thereof. The product further includes a first encapsulant of the composition and a prill coating on the first encapsulant.
- In another embodiment, the invention is directed to a product that includes a composition comprising a labile compound with a first encapsulant of the composition and a second encapsulant of the first encapsulant. In this embodiment, the product further comprises a Maillard reaction product formed by contacting the first encapsulant with the second encapsulant.
- In another embodiment, the invention is directed to a product that includes a composition comprising a labile compound with a first encapsulant of the composition and a second encapsulant of the first encapsulant. In this embodiment, the second encapsulant further comprises a Maillard reaction product.
- In an additional embodiment, the invention is directed to a product that includes a composition comprising a labile compound with a first encapsulant of the composition and a second encapsulant of the first encapsulant. In this embodiment, the product further comprises a Maillard reaction product formed in a non-aqueous environment.
- As used herein, a labile compound is a compound that will readily undergo a chemical and/or biological change or breakdown; that is, a compound that undergoes a noticeable change under intended use conditions. E.g., a PUFA in a food product can undergo some degradation in palatability that is noticeable by a consumer of the food product. Such conditions can be defined in terms of temperature, storage time, presence of water, and the like. Labile compounds include, without limitation, polyunsaturated fatty acids (PUFAs), vitamins, minerals, antioxidants, hormones, amino acids, proteins, carbohydrates, coenzymes, flavor agents and mixtures of the foregoing. In a further embodiment, the labile compound can be selected from PUFAs, vitamins, minerals, antioxidants, hormones, amino acids, proteins, carbohydrates, coenzymes, and mixtures thereof. The labile compound can be in the form of a solid particle, a liquid droplet, a gas bubble, or mixtures of these. In one preferred embodiment, the labile compound is a solid particle, and in another preferred embodiment, the labile compound is a liquid.
- In some embodiments of the invention, the labile compound is a PUFA. In some embodiments, a PUFA has a chain length of at least 18 carbons. Such PUFAs are referred to herein as long chain PUFAs or LC PUFAs. In some embodiments, the PUFA can be docosahexaenoic acid C22:6(n-3) (DHA), omega-3 docosapentaenoic acid C22:5(n-3) (DPA(n-3)), omega-6 docosapentaenoic acid C22:5(n-6) (DPA(n-6)), arachidonic acid C20:4(n-6) (ARA), eicosapentaenoic acid C20:5(n-3) (EPA), stearidonic acid, linolenic acid, alpha linolenic acid (ALA), gamma linolenic acid (GLA), conjugated linolenic acid (CLA) or mixtures thereof. The PUFAs can be in any of the common forms found in natural lipids including but not limited to triacylglycerols, diacylglycerols, monoacylglycerols, phospholipids, free fatty acids, or in natural or synthetic derivative forms of these fatty acids (e.g. calcium salts of fatty acids, esters of fatty acids, including methyl esters, ethyl esters, and the like). Reference to an oil or other composition comprising an LC PUFA, as used in the present invention, can refer to either a composition comprising only a single LC PUFA such as DHA or a composition comprising a mixture of LC PUFAs such as DHA and EPA, or DHA and ARA.
- While certain embodiments are described herein with reference to PUFAs for the sake of convenience and conciseness, it is to be understood that products comprising other labile compounds are included within the scope of the invention. PUFAs can be obtained from or derived from a plant (including oilseeds; as one skilled in the art will appricea, an oilseed is part of a plant), a microorganism, an animal, or mixtures of the foregoing. The microorganisms can be algae, bacteria, fungi or protists. Microbial sources and methods for growing microorganisms comprising nutrients and/or PUFAs are known in the art (Industrial Microbiology and Biotechnology, 2nd edition, 1999, American Society for Microbiology). For example, the microorganisms can be cultured in a fermentation medium in a fermentor. PUFAs produced by microorganisms can be used in the methods and compositions of the present invention. In some embodiments, organisms include those selected from the group consisting of golden algae (such as microorganisms of the kingdom Stramenopiles), green algae, diatoms, dinoflagellates (such as microorganisms of the order Dinophyceae including members of the genus Crypthecodinium such as, for example, Crypthecodinium cohnii), yeast, and fungi of the genera Mucor and Mortierella, including but not limited to Mortierella alpina and Mortierella sect. schinuckeri. Members of the microbial group Stramenopiles include microalgae and algae-like microorganisms, including the following groups of microorganisms: Hamatores, Proteromonads, Opalines, Develpayella, Diplophrys, Labrinthulids, Thraustochytrids, Biosecids, Oomycetes, Hypochytridiomycetes, Commation, Reticulosphaera, Pelagomonas, Pelagococcus, Ollicola, Aureococcus, Parmales, Diatoms, Xanthophytes, Phaeophytes (brown algae), Eustigmatophytes, Raphidophytes, Synurids, Axodines (including Rhizochromulinaales, Pedinellales, Dictyochales), Chrysorneridales, Sarcinochrysidales, Hydrurales, Hibberdiales, and Chromulinales. The Thraustochytrids include the genera Schizochytrium (species include aggregatum, limnaceum, mangrovei, minutum, octosporum), Thraustochytrium (species include arudimentale, aureum, benthicola, globosum, kinnei, motivum, multirudimentale, pachyderinum, proliferuin, roseum, striatum
- ), Ulkenia (species include amoeboidea, kerguelensis, minuta, profunda, radiate, sailens, sarkariana, schizochytrops, visurgensis, yorkensis), Aplanochytrium (species include haliotidis, kerguelensis, profunda, stocchinoi), Japonochytrium (species include marinum), Althornia (species include crouchii), and Elina (species include marisalba, sinorifica). The Labrinthulids include the genera Labyrinthula (species include algeriensis, coenocystis, chattonii, macrocystis, macrocystis atlantica, macrocystis macrocystis, mairina, minuta, roscoffensis, valkanovii, vitellina, vitellina pacifica, vitellina vitellina, zopfi), Labyrinthomyxa (species include marina), Labyrinthuloides (species include haliotidis, yorkensis), Diplophrys (species include archeri), Pyrrhosorus* (species include marinus), Sorodiplophrys* (species include stercorea), Chlamydomyxa* (species include labyrinthuloides, montana). (*=there is no current general consensus on the exact taxonomic placement of these genera).
- Suitable microorganisms include those capable of producing lipids comprising the labile compounds omega-3 and/or omega-6 polyunsaturated fatty acids, and in particular microorganisms that are capable of producing DHA, DPA, EPA or ARA) will be described. More particularly, preferred microorganisms are algae, such as Thraustochytrids of the order Thraustochytriales, including Thraustochytrium (including Ulkenia) and Schizochytrium and including Thraustochytriales which are disclosed in commonly assigned U.S. Pat. Nos. 5,340,594 and 5,340,742, both issued to Barclay, all of which are incorporated herein by reference in their entirety. More preferably, the microorganisms are selected from the group consisting of microorganisms having the identifying characteristics of ATCC number 20888, ATCC number 20889, ATCC number 20890, ATCC number 20891 and ATCC number 20892. Since there is some disagreement among experts as to whether (lkenia is a separate genus from the genus Thraustochytrium, for the purposes of this application, the genus Thraustochytrium will include Ulkenia. Also preferred are strains of Mortierella schmuckeri (e.g., including ATCC 74371) and Mortierella alpina. Also preferred are strains of Crypthecodinium cohnii, including microorganisms having the identifying characteristics of ATCC Nos. 30021, 30334-30348, 30541-30543, 30555-30557, 30571, 30572, 30772-30775, 30812, 40750, 50050-50060, and 50297-50300. Oleaginous microorganisms are also preferred. As used herein, “oleaginous microorganisms” are defined as microorganisms capable of accumulating greater than 20% of the dry weight of their cells in the form of lipids. Genetically modified microorganisms that produce PUFAs are also suitable for the present invention. These can include naturally PUFA-producing microorganisms that have been genetically modified as well as microorganisms that do not naturally produce PUFAs but that have been genetically modified to do so.
- Suitable organisms can be obtained from a number of available sources, including by collection from the natural environment. For example, the American Type Culture Collection currently lists many publicly available strains of microorganisms identified above. As used herein, any organism, or any specific type of organism, includes wild strains, mutants, or recombinant types. Growth conditions in which to culture or grow these organisms are known in the art, and appropriate growth conditions for at least some of these organisms are disclosed in, for example, U.S. Pat. No. 5,130,242, U.S. Pat. No. 5,407,957, U.S. Pat. No. 5,397,591, U.S. Pat. No. 5,492,938, and U.S. Pat. No. 5,711,983, all of which are incorporated herein by reference in their entirety.
- Another source of PUFAs, in the compositions and methods of the present invention includes a plant source, such as oilseed plants. PUFA-producing plants, in alternate embodiments, can include those genetically engineered to express genes that produce PUFAs and those that produce PUFAs naturally. Such genes can include genes encoding proteins involved in the classical fatty acid synthase pathways, or genes encoding proteins involved in the PUFA polyketide synthase (PKS) pathway. The genes and proteins involved in the classical fatty acid synthase pathways, and genetically modified organisms, such as plants, transformed with such genes, are described, for example, in Napier and Sayanova, Proceedings of the Nutrition Society (2005), 64:387-393; Robert et al., Functional Plant Biology (2005) 32:473-479; or U.S. Patent Application Publication 2004/0172682. The PUFA PKS pathway, genes and proteins included in this pathway, and genetically modified microorganisms and plants transformed with such genes for the expression and production of PUFAs are described in detail in: U.S. Pat. No. 6,566,583; U.S. Patent Application Publication No. 20020194641, U.S. Patent Application Publication No. 20040235127A1, and U.S. Patent Application Publication No. 20050100995A1, each of which is incorporated herein by reference in its entirety.
- Oilseed crops suitable for use in the present invention include soybeans, corn, safflower, sunflower, canola, flax, peanut, mustard, rapeseed, chickpea, cotton, lentil, white clover, olive, palm oil, borage, evening primrose, linseed, and tobacco that have been genetically modified to produce PUFA as described above.
- Genetic transformation techniques for microorganisms and plants are well-known in the art. Transformation techniques for microorganisms are well known in the art and are discussed, for example, in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Labs Press. A general technique for transformation of dinoflagellates, which can be adapted for use with Crypthecodinium cohnii, is described in detail in Lohuis and Miller, The Plant Journal (1998) 13(3): 427-435. A general technique for genetic transformation of Thraustochytrids is described in detail in U.S. Patent Application Publication No. 20030166207, published Sep. 4, 2003. Methods for the genetic engineering of plants are also well known in the art. For instance, numerous methods for plant transformation have been developed, including biological and physical transformation protocols. See, for example, Miki et al., “Procedures for Introducing Foreign DNA into Plants” in Methods in Plant Molecular Biology and Biotechnology, Glick, B. R. and Thompson, J. E. Eds. (CRC Press, Inc., Boca Raton, 1993) pp. 67-88. In addition, vectors and in vitro culture methods for plant cell or tissue transformation and regeneration of plants are available. See, for example, Gruber et al., “Vectors for Plant Transformation” in Methods in Plant Molecular Biology and Biotechnology, Glick, B. R. and Thompson, J. E. Eds. (CRC Press, Inc., Boca Raton, 1993) pp. 89-119. See also, Horsch et al., Science 227:1229 (1985); Kado, C. I., Crit. Rev. Plant. Sci. 10:1 (1991); Moloney et al., Plant Cell Reports 8:238 (1989); U.S. Pat. No. 4,940,838; U.S. Pat. No. 5,464,763; Sanford et al., Part. Sci. Technol. 5:27 (1987); Sanford, J. C., Trends Biotech. 6:299 (1988); Sanford, J. C., Physiol Plant 79:206 (1990); Klein et al., Biotechnology 10:268 (1992); Zhang et al., Bio/Technology 9:996 (1991); Deshayes et al., EMBO J, 4:2731 (1985); Christou et al., Proc Natl. Acad. Sci. USA 84:3962 (1987); Hain et al., Mol. Gen. Genet. 199:161 (1985); Draper et al., Plant Cell Physiol. 23:451 (1982); Donn et al., In Abstracts of VIIth International Congress on Plant Cell and Tissue Culture IAPTC, A2-38, p. 53 (1990); D'Halluin et al., Plant Cell 4:1495-1505 (1992) and Spencer et al., Plant Mol. Biol. 24:51-61 (1994).
- When oilseed plants are the source of PUFAs, the seeds can be harvested and processed to remove any impurities, debris or indigestible portions from the harvested seeds. Processing steps vary depending on the type of oilseed and are known in the art. Processing steps can include threshing (such as, for example, when soybean seeds are separated from the pods), dehulling (removing the dry outer covering, or husk, of a fruit, seed, or nut), drying, cleaning, grinding, milling and flaking. After the seeds have been processed to remove any impurities, debris or indigestible materials, they can be added to an aqueous solution and then mixed to produce a slurry. In some embodiments, milling, crushing or flaking is performed prior to mixing with water. A slurry produced in this manier can be treated and processed the same way as described for a microbial fermentation broth.
- Another biomass source of nutrients, including PUFAs, in the compositions and methods of the present invention includes an animal source. Examples of animal sources include aquatic animals (e.g., fish, marine mammals, and crustaceans such as krill and other eupliausids) and animal tissues (e.g., brain, liver, eyes, etc.) and animal products such as eggs or milk. Techniques for recovery of PUFA-containing oils from such sources are known in the art.
- In some embodiments, the labile compound is a vitamin, such as, for example, Vitamin A, Vitamin D, Vitamin E, Vitamin K, Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B6, Vitamin C, Folic Acid, Vitamin B-12, Biotin, Vitamin B5 or mixtures thereof.
- In some embodiments, the labile compound is mineral, such as, for example, calcium, iron, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, ionic fonns of the foregoing, biologically acceptable salts of the foregoing, or mixtures thereof.
- In some embodiments, the labile compound comprises an antioxidant, carotenoid or xanthophyll, such as, for example, lycopene, lutein, zeaxanthin, astaxanthin, alpha-lipoic acid, coenzymeQ, beta-carotene or mixtures thereof.
- In some embodiments, the labile compound is an amino acid, such as, for example, arginine, aspartic acid, carnitine, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, SAM-e or mixtures thereof.
- In some embodiments, the labile compound comprises a flavor agent, such as a flavor (or essential) oil, oleoresin, other flavoring essence or mixtures thereof. The term flavor oil is generally recognized in the art to be a flavoring aromatic compound and/or oil or extract derived from botanical sources, i.e. leaves, bark, or skin of fruits or vegetables, and which are usually insoluble in water. Examples of flavor oils include peppermint oil, spearmint oil, cinnamon oil, oil of wintergreen, nut oil, licorice, vanilla, citrus oils, fruit essences and mixtures thereof. Citrus oils and fruit essences include apple, apricot, banana, blueberry, cherry, coconut, grape, grapefruit, lemon, lime, orange, pear, peaches, pineapple, plum, raspberry, strawberry, and mixtures thereof. Oleoresin extracts of spices includes, for example oleoresin extracts of tarragon, thyme, sage, rosemary, oregano, nutmeg, basil, bay, cardamom flavor, celery, cilantro, cinnamon, clove, coriander, cumin, fennel, garlic, ginger, mace, marjoram, capsicum, black pepper, white pepper, annatto, paprika, turmeric, cajun, and mixtures thereof.
- Without intending to be bound by any theory, the first encapsulant is believed to protect the composition comprising the labile compound to reduce the likelihood of or degree to which the labile compound undergoes a chemical, physical, or biological change or breakdown. The first encapsulant can form a continuous coating on the composition comprising the labile compound (100% encapsulation) or alternatively, form a non-continuous coating (e.g., at a level that provides substantial coverage of the labile compound, for example, coverage at 80%, 90%, 95%, or 99%). In other embodiments, the first encapsulant can be a matrix in which the labile compound is entrapped.
- In various embodiments, the composition comprising the labile compound with a first encapsulant can be any of an encapsulated composition comprising a labile compound, a whole cell biomass, a biomass hydrolysate, or an oilseed.
- Encapsulation of compositions comprising labile compounds, including PUFAs, with a first encapsulant can be by any method known in the art. For example, the composition comprising a labile compound can be spray-dried. Other methods for encapsulation are known, such as fluid bed drying, drum (film) drying, coacervation, interfacial polymerization, fluid bed processing, pan coating, spray gelation, ribbon blending, spinning disk, centrifugal coextrusion, inclusion complexation, emulsion stabilization, spray coating, extrusion, liposome nanoencapsulation, supercritical fluid microencapsulation, suspension polymerization, cold dehydration processes, spray cooling/chilling (prilling), evaporative dispersion processes, and methods that take advantage of differential solubility of coatings at varying temperatures.
- Some exemplary encapsulation techniques are summarized below. It should be recognized that reference to the various techniques summarized below includes the description herein and variations of those descriptions known to those in the art.
- In spray drying, the core material to be encapsulated is dispersed or dissolved in a solution. Typically, the solution is aqueous and the solution includes a polymer. The solution or dispersion is pumped through a micronizing nozzle driven by a flow of compressed gas, and the resulting aerosol is suspended in a heated cyclone of air, allowing the solvent to evaporate from the microdroplets. The solidified microparticles pass into a second chamber and are trapped in a collection flask.
- Interfacial polycondensation is used to encapsulate a core material in the following manner. One monomer and the core material are dissolved in a solvent. A second monomer is dissolved in a second solvent (typically aqueous) which is immiscible with the first. An emulsion is formed by suspending the first solution in the second solution by stirring. Once the emulsion is stabilized, an initiator is added to the aqueous phase causing interfacial polymerization at the interface of each droplet of emulsion.
- In hot melt encapsulation the core material is added to molten polymer. This mixture is suspended as molten droplets in a nonsolvent for the polymer (often oil-based) which has been heated to approximately 10° C. above the melting point of the polymer. The emulsion is maintained through vigorous stirring while the nonsolvent bath is quickly cooled below the glass transition of the polymer, causing the molten droplets to solidify and entrap the core material.
- In solvent evaporation encapsulation, a polymer is typically dissolved in a water immiscible organic solvent and the material to be encapsulated is added to the polymer solution as a suspension or solution in organic solvent. An emulsion is formed by adding this suspension or solution to a vessel of vigorously stirred water (often containing a surface active agent to stabilize the emulsion). The organic solvent is evaporated while continuing to stir. Evaporation results in precipitation of the polymer, forming solid microcapsules containing core material.
- The solvent evaporation process is designed to entrap a liquid core material in a polymer, copolymer, or copolymer microcapsules. The polymer or copolymer is dissolved in a miscible mixture of solvent and nonsolvent, at a nonsolvent concentration which is immediately below the concentration which would produce phase separation (i.e., cloud point). The liquid core material is added to the solution while agitating to form an emulsion and disperse the material as droplets. Solvent and nonsolvent are vaporized, with the solvent being vaporized at a faster rate, causing the polymer or copolymer to phase separate and migrate towards the surface of the core material droplets. This phase separated solution is then transferred into an agitated volume of nonsolvent, causing any remaining dissolved polymer or copolymer to precipitate and extracting any residual solvent from the formed membrane. The result is a microcapsule composed of polymer or copolymer shell with a core of liquid material.
- In solvent removal encapsulation, a polymer is typically dissolved in an oil miscible organic solvent and the material to be encapsulated is added to the polymer solution as a suspension or solution in organic solvent. An emulsion is formed by adding this suspension or solution to a vessel of vigorously stirring oil, in which the oil is a nonsolvent for the polymer and the polymer/solvent solution is immiscible in the oil. The organic solvent is removed by diffusion into the oil phase while continuing to stir. Solvent removal results in precipitation of the polymer, forming solid microcapsules containing core material.
- In phase separation encapsulation, the material to be encapsulated is dispersed in a polymer solution by stirring. While continuing to uniformly suspend the material through stirring, a nonsolvent for the polymer is slowly added to the solution to decrease the polymer's solubility. Depending on the solubility of the polymer in the solvent and nonsolvent, the polymer either precipitates or phase separates into a polymer rich and a polymer poor phase. Under proper conditions, the polymer in the polymer rich phase will migrate to the interface with the continuous phase, encapsulating the core material in a droplet with an outer polymer shell.
- Spontaneous emulsification involves solidifying emulsified liquid polymer droplets by changing temperature, evaporating solvent, or adding chemical cross-linking agents. Physical and chemical properties of the encapsulant and the material to be encapsulated dictates suitable methods of encapsulation. Factors such as hydrophobicity, molecular weight, chemical stability, and thermal stability affect encapsulation.
- Coacervation is a process involving separation of colloidal solutions into two or more immiscible liquid layers (Dowben, R. General Physiology, Harper & Row, New York, 1969, pp. 142-143). Through the process of coacervation compositions comprised of two or more phases and known as coacervates may be produced. The ingredients that comprise the two phase coacervate system are present in both phases; however, the colloid rich phase has a greater concentration of the components than the colloid poor phase.
- Low temperature microsphere formation has been described, see, e.g., U.S. Pat. No. 5,019,400. The method is a process for preparing microspheres which involves the use of very cold temperatures to freeze polymer-biologically active agent mixtures into polymeric microspheres. The polymer is generally dissolved in a solvent together with an active agent that can be either dissolved in the solvent or dispersed in the solvent in the form of microparticles. The polymer/active agent mixture is atomized into a vessel containing a liquid non-solvent, alone or frozen and overlayed with a liquefied gas, at a temperature below the freezing point of the polymer/active agent solution. The cold liquefied gas or liquid immediately freezes the polymer droplets. As the droplets and non-solvent for the polymer is warmed, the solvent in the droplets thaws and is extracted into the non-solvent, resulting in hardened microspheres.
- Phase separation encapsulation generally proceeds more rapidly than the procedures described in the preceding paragraphs. A polymer is dissolved in the solvent. An agent to be encapsulated then is dissolved or dispersed in that solvent. The mixture then is combined with an excess of nonsolvent and is emulsified and stabilized, whereby the polymer solvent no longer is the continuous phase. Aggressive emulsification conditions are applied in order to produce microdroplets of the polymer solvent. After emulsification, the stable emulsion is introduced into a large volume of nonsolvent to extract the polymer solvent and form microparticles. The size of the microparticles is determined by the size of the microdroplets of polymer solvent.
- Another method for encapsulating is by phase inversion nanoencapsulation (PIN). In PIN, a polymer is dissolved in an effective amount of a solvent. The agent to be encapsulated is also dissolved or dispersed in the effective amount of the solvent. The polymer, the agent and the solvent together form a mixture having a continuous phase, wherein the solvent is the continuous phase. The mixture is introduced into an effective amount of a nonsolvent to cause the spontaneous formation of the microencapsulated product, wherein the solvent and the nonsolvent are miscible.
- In preparing a first encapsulant of a composition comprising a labile compound the conditions can be controlled by one skilled in the art to yield encapsulated material with the desired attributes. For example, the average particle size, hydrophobicity, biocompatibility, ratio of core material to encapsulant, thermal stability, and the like can be varied by one skilled in the art.
- In the instance where the composition comprising the labile compound with a first encapsulant comprises a whole cell biomass, it will be recognized that the cell, e.g., a microbial cell, can include a labile compound such as a PUFA, a vitamin or other beneficial compound. Whole cells include those described above as sources for PUFAs. The cellular structure (e.g., a cell wall or cell membrane), at least in part, constitutes the first encapsulant and it provides protection to the labile compound by virtue of isolating it from the surrounding environment. As used herein, biomass can refer to multiple whole cells that, in the aggregate, constitute a biomass. A microbial biomass can refer to a biomass that has not been separated from the culture media in which the biomass organism was cultured. An example of a culture media is a fermentation broth. In a further embodiment, the biomass is separated from its culture media by a solid/liquid separation prior to treatment by methods of the present invention. Typical solid/liquid separation techniques include centrifugation, filtration, and membrane filter pressing (plate and frame filter press with squeezing membranes). This (harvested) biomass usually has a dry matter content varying between 5% and 60%. If the water content is too high, the biomass can be dewatered by any method known in the art, such as, for example, spray drying, fluidized bed drying, lyophilization, freeze drying, tray drying, vacuum tray drying, drum drying, solvent drying, excipient drying, vacuum mixer/reactor drying, drying using spray bed drying, fluidized spray drying, conveyor drying, ultrafiltration, evaporation, osmotic dehydration, freezing, extrusion, absorbent addition or other similar methods, or combinations thereof. The drying techniques referenced herein are well known in the art. For example, excipient drying refers to the process of atomizing liquids onto a bed of material such as starch and solvent drying refers to a process where a solvent, miscible with water, is used in excess to replace the water. The biomass can optionally be washed in order to reduce extracellular components. The fermentation broth can be dried and then reconstituted to a moisture content of any desired level before treatment by any of the methods of the present invention. Alternatively, hydrolyzing enzymes can be applied to dried biomass to form a biomass hydrolysate, described elsewhere herein.
- In a further embodiment in which the composition comprising the labile compound with a first encapsulant comprises a whole cell, the whole cell is a probiotic organism. As is well understood, probiotics are microorganisms that are intended to confer a beneficial health effect when consumed by favorably altering the intestinal microflora balance, inhibiting the growth of harmful bacteria, producing beneficial compositions, promoting good digestion, boosting immune function, and/or increasing resistance to infection. For example, Lactobacillus acidophilus is considered to be beneficial because it produces vitamin K, lactase, and anti-microbial substances such as acidolin, acidolphilin, lactocidin, and bacteriocin. Probiotics include, for example, lactic acid bacteria, and bifidobacteria. Lactic acid bacteria include, for example, Lactococcus lactis, Lactobacillus acidolphilus, Lactobacillus crispatus, Lactobacillus amylovorous, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus rhamnosus, Lactobacillus brevis, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus helveticus, Lactobacillus casei, Lactobacillus delbruckii, Lactobacillus bulgaricus, Lactobacillus plantarum, and Lactobacillus GG. Bifidobacteria include, for example, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, and Bifidobacterium longum. Additional probiotic bacteria include, for instance, Streptococcus thermophilus and Leuconostoc mesenteroides. Without intending to be bound by theory, the beneficial effects of these microorganisms can be preserved if encapsulated by a second encapsulant. In one embodiment, the probiotic microorganism is encapsulated under conditions in which the microorganism retains its beneficial probiotic properties. For example, encapsulation with a second encapsulant can be performed at a temperature lower than the temperature required for inactivation of the microorganism, generally in the range of 90-100° C.
- In a further embodiment, the composition comprising the labile compound with a first encapsulant comprises an emulsified biomass hydrolysate. Such compositions and methods for making the same are described in detail in U.S. Provisional Patent Application Ser. No. 60/680,740, filed on May 12, 2005; U.S. Provisional Patent Application Ser. No. 60/781,430, filed on Mar. 10, 2006; and U.S. patent application Ser. No. 11/433,752, filed on May 12, 2006, all of which are incorporated herein by reference. Briefly, an emulsified biomass hydrolysate is obtained by hydrolyzing a nutrient-containing biomass to produce a hydrolyzed biomass, and emulsifying the hydrolyzed biomass to fonn a stable product. The stable product is typically an emulsion or a dry composition resulting from subsequent drying of the emulsion.
- In a further embodiment, the composition comprising the labile compound with a first encapsulant comprises an oilseed. Such oilseeds can be selected from those generally described above as sources for PUFAs and can include oilseeds from plants that have been genetically modified and plants that have not been genetically modified.
- As noted above, products of the present invention include a second encapsulant of the first encapsulant. Without intending to be bound by theory, the second encapsulant of the first encapsulant is believed to further protect the composition comprising the labile compound to reduce the likelihood of or degree to which the labile compound undergoes a chemical, physical, or biological change or breakdown. The second encapsulant can form a continuous coating on the first encapsulant (100% encapsulation) or alternatively, fonn a non-continuous coating (e.g., at a level that provides substantial coverage of the first encapsulant, for example, coverage at 80%, 90%, 95%, or 99%). In other embodiments, the second encapsulant can be a matrix in which the first encapsulant is entrapped.
- The second encapsulant can be applied by any method known in the art, such as spray drying, fluid bed drying, drum (film) drying, coacervation, interfacial polymerization, fluid bed processing, pan coating, spray gelation, ribbon blending, spinning disk, centrifugal coextrusion, inclusion complexation, emulsion stabilization, spray coating, extrusion, liposome nanoencapsulation, supercritical fluid microencapsulation, suspension polymerization, cold dehydration processes, spray cooling/chilling (prilling), evaporative dispersion processes, and methods that take advantage of differential sohlbility of coatings at varying temperatures. While a second encapsulant can encapsulate a single discrete particle (i.e., a particle that is a first encapsulant of a composition comprising a labile compound), a second encapsulant can alternatively encapsulate a plurality of discrete particles within a single second encapsulant.
- In preferred embodiments, the second encapsulant of the first encapsulant is a prill coating. Prilling is a process of encapsulating compounds in a high temperature melt matrix wherein the prilling material goes from solid to liquid above room temperature. As used herein, a prill coating is a wax, oil, fat, or resin, typically having a melting point of about 25-150° C. The prill coating can envelop the first encapsulant completely (100% encapusulation), or the prill coating can envelop the first encapsulant at some level less than 100%, but at a level which provides substantial coverage of the first encapsulant, for example, at about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, or about 99%. In some embodiments, the prill coating is edible. More particularly, the prill coating can comprise, for example, a fatty acid monoglyceride; a fatty acid diglyceride; a fatty acid triglyceride; a free fatty acid (such as stearic acid, palmitic acid, and oleic acid); tallow (such as beef tallow, mutton tallow, and lamb tallow); lard (pork fat); beeswax; lanolin; shell wax; insect wax including Chinese insect wax; vegetable wax, carnauba wax; candelilla wax; bayberry wax; sugar cane wax; mineral wax; paraffin microcrystalline petroleum wax; ozocerite wax; ceresin wax; montan synthetic wax, low molecular weight polyolefin; polyol ether-esters, sorbitol; Fischer-Tropsch process synthetic wax; rosin; balsam; shellac; stearylamide; ethylenebisstearylamide; hydrogenated castor oil; esters of pentaerythritol; mono and tetra esters of stearic acid; vegetable oil (such as cottonseed oil, sunflower oil, safflower oil, soybean oil, corn oil, olive oil, canola oil, linseed oil, flaxseed oil); hydrogenated vegetable oil; and mixtures and derivatives of the foregoing. In some embodiments, the prill coating is hydrogenated cottonseed oil, hydrogenated sunflower oil, hydrogenated safflower oil, hydrogenated soybean oil, hydrogenated corn oil, hydrogenated olive oil, hydrogenated canola oil, hydrogenated linseed oil, or hydrogenated flaxseed oil.
- In some embodiments, the prill coating further comprises an additional component. The additional component can be, for example, a fat-soluble or fat dispersible antioxidant, oxygen scavenger, colorant or flavor agent. Such an antioxidant can be, for example, vitamin E, tocopherol, butylhydroxytoluene (BHT), butylhydroxyanisole (BHA), tert-butylhydroquinone (TBHQ), propyl gallate (PG), vitamin C, ascorbyl palmitate, phospholipids, a Maillard reaction product, natural antioxidants (such as spice extracts, e.g., rosemary or oregano extracts, and seed extracts, e.g., grapeseed extracts or pomegranate extract), and combinations thereof. The Maillard reaction product can be added as an antioxidant in addition to Maillard reaction products described elsewhere. Such an oxygen scavenger can be, for example, ascorbic acid, isoascorbic acid, erythorbic acid, or mixtures of salts thereof. The colorant component is selected from the group consisting of water soluble natural or artificial dyes that include FD&C dyes (food, drug and cosmetic use dyes) of blue, green, orange, red, yellow and violet; iron oxide dyes; ultramarine pigments of blue, pink, red and violet; and equivalents thereof. The dyes discussed above are well known, and are commercially available materials. Examples of flavor agents include flavor oils such as peppermint oil, spearmint oil, cinnamon oil, oil of wintergreen, nut oil, licorice, vanilla, citrus oils, fruit essences and mixtures thereof. Citrus oils and fruit essences include apple, apricot, banana, blueberry, cherry, coconut, grape, grapefruit, lemon, lime, orange, pear, peaches, pineapple, plum, raspberry, strawberry, and mixtures thereof. Other examples of flavor agents include oleoresin extracts of spices includes, for example oleoresin extracts of tarragon, thyme, sage, rosemary, oregano, nutmeg, basil, bay, cardamom flavor, celery, cilantro, cinnamon, clove, coriander, cumin, fennel, garlic, ginger, mace, marjoram, capsicum, black pepper, white pepper, annatto, paprika, turmeric, cajun, and mixtures thereof.
- In some embodiments, the prill coating is applied by a prilling method with the resultant product being a prill or bead. Prilling is also known in the art as spray cooling, spray chilling, and/or matrix encapsulation. Prilling is similar to spray drying in that a core material, in the present case, a first encapsulant of a composition comprising a labile compound, is dispersed in a liquefied coating or wall material and atomized. Unlike spray drying, there is no water present to be evaporated. The core material and the second encapsulant can be atomized into cooled or chilled air, which causes the wall to solidify around the core. In spray chilling, the prill coating typically has a melting point between about 32° C. and about 42° C. In spray cooling, the prill coating typically has a melting point of between about 45° C. and about 122° C. In some embodiments, the prill coating is applied by a modified prilling method. A modified prilling method, for example, can be a spinning disk process or centrifugal coextrusion process. In some embodiments, the product having a prill coating is in a form that results in a free-flowing powder.
- In some embodiments, the prill coating is applied so as to form a product into configurations other than powders, such as chips or flakes. In all such embodiments, the equipment converts the liquid prill coating material into a solid by cooling it while it is applied to a first encapsulated product. For example, the prill coating and first encapsulant of a composition comprising a labile compound are cooled as the mixture passes through rollers and is formed into a flat sheet, which can then be processed into chips or flakes. Alternatively, the mixture can be extruded through dies to form shapes or through blades to be cut into ribbons.
- In a further embodiment, the second encapsulant of the first encapsulant is a fluid bed coating. Application of a fluid bed coating is well suited to uniformly coat or encapsulate individual particulate materials. The apparatus for applying a fluid bed coating is typically characterized by the location of a spray nozzle at the bottom of a fluidized bed of solid particles, and the particles are suspended in a fluidizing air stream that is designed to induce cyclic flow of the particles past the spray nozzle. The nozzle sprays an atomized flow of coating solution, suspension, or other coating material. The atomized coating material collides with the particles as they are carried away from the nozzle. The temperature of the fluidizing air is set to appropriately solidify the coating material shortly after colliding with the particles. Suitable coating materials include the materials identified above as materials for prill coatings. For example, hot-melt coatings are a solid fat (at room temperature) that has been melted and sprayed on to a particle (i.e., a first encapsulant) where it solidifies. A benefit of using hot-melt coatings is that they have no solvent to evaporate and are insoluble in water, they are also low cost and easily obtainable. Typical coating volume for hot-melt application to a first encapsulant is 50% (one half hot-melt coating and one half first encapsulant and core material).
- Additional encapsulants, for example, a third encapsulant, a fourth encapsulant, a fifth encapsulant, and so on, are also contemplated in the present invention. Additional encapsulants can be applied by methods described herein, and can provide additional desirable properties to the products. For example, the additional encapsulants can further enhance the shelf life of the products, or modify the release properties of the product to provide for controlled release or delayed release of the labile compound.
- In some embodiments, the product further comprises a Maillard reaction product (MRP). The Maillard reaction occurs when reducing sugars and amino acids react. A reducing sugar is a sugar with a ketone or an aldehyde functional group, which allows the sugar to act as a reducing agent in the Maillard reaction. This reaction occurs in most foods on heating. Maillard reaction chemistry can affect desirable flavors and color of a wide range of foods and beverages. While not being bound by theory, it is believed that formation of MRPs in the products of the invention produces aromas and flavors that are desirable for inclusion in food products or other products that are consumed. MRPs can also possess antioxidant activity, and without being bound by theory, it is believed that this property of the MRPs imparts increased stability and shelf life to the products of the present invention. The Maillard reactions are well-known and from the detailed specification herein, temperature and time required to carry the reaction to the desired extent can be determined.
- MRPs can be included in the products of the present invention in a number of ways. In some embodiments, the MRP is a product of a reducing sugar and an amino acid source that is a protein. Proteins that can be used to produce an MRP include casein, whey solids, whey protein isolate, soy protein, skim milk powder, hydrolyzed casein, hydrolyzed whey protein, hydrolyzed soy protein, non-fat milk solids, gelatin, zein, albumin, and the like. Alternatively, amino acids can be provided directly or by in situ formation, such as by acid, alkaline or enzymatic hydrolysis. In various embodiments, the reducing sugar can include sugars, such as fructose, glucose, glyceraldehyde, lactose, arabinose, and maltose. As used herein, the term reducing sugar also includes complex sources of reducing sugars. For example, suitable complex sources include corn syrup solids and modified starches such as chemically modified starches and hydrolysed starches or dextrins, such as maltodextrin. Hydrolysed starches (dextrins) are used in some embodiments. In some embodiments, the reducing sugar is formed in situ from, for example, a compound that is not itself a reducing sugar, but comprises reducing sugars. For example, starch is not a reducing sugar, but is a polymer of glucose, which is a reducing sugar. Hydrolysis of starch, by chemical or enzymatic means, yields glucose. This hydrolysis can take place in situ, to provide the reducing sugar glucose.
- The reducing sugars and protein used to form MRPs in various embodiments of the present invention can naturally occur in the first encapsulant of the composition or the second encapsulant. For example, in the instance of the first encapsulant being a microbial biomass hydrolysate emulsion, the reducing sugars and proteins can be present without being added. Alternatively, various embodiments of the invention contemplate the addition of some or all of the reducing sugar and protein.
- In one embodiment, an MRP is formed by contacting the first encapsulant with the second encapsulant. Thus, the invention provides in a further embodiment, a product comprising a composition comprising a labile compound, a first encapsulant of the composition, and a second encapsulant of the first encapsulant, wherein the product further comprises an MRP formed by contacting the first encapsulant with the second encapsulant. In this embodiment, at the time the first encapsulant and second encapsulants are brought into contact, they are done so in the presence of reducing sugars and protein under suitable temperature and time conditions to form MRPs. For example, when the second encapsulant is a prill coating, contacting the first encapsulant with the liquefied prill coating at elevated temperature in the presence of reducing sugars and proteins can promote the formation of MRPs. In general, the temperature of such a reaction ranges from about 20° C. to about 150° C. with from about 80° C. to about 110° C. being preferred. The time of the reaction ranges from about 1 minute to about several hours, depending on the temperature. At the preferred higher temperature range, the time of reaction is preferably about 1 minute to about 20 minutes. Reference to “time of reaction” in this paragraph refers to the time that the first encapsulant is in contact with the liquefied prill coating before cooling to solidify the coating.
- In another embodiment, the Maillard reaction product is formed in a non-aqueous environment. Accordingly, in one embodiment, the invention provides a product comprising a composition comprising a labile compound, a first encapsulant of the composition, and a second encapsulant of the first encapsulant, wherein the product further comprises a Maillard reaction product formed in a non-aqueous environment. For example, when the second encapsulant is a prill coating, contacting the first encapsulant with the liquefied prill coating at elevated temperature in the presence of reducing sugars and proteins can promote the formation of MRPs in the environment of the liquefied prill coating, i.e., a non-aqueous environment. In this embodiment, the reaction is analogous to browning in oil. Water is produced as a byproduct of the Maillard reaction, and therefore the presence of water is inhibitory for the formation of MRPs. Thus, it should be recognized that reference to a non-aqueous environment, encompasses an environment comprising small amounts of water, such as that produced by the Maillard reaction. By carrying out the Maillard reaction in a non-aqueous environment, it is believed that the reaction occurs more readily than it would in the presence of water and that reaction times are therefore reduced significantly. Additionally, undesirable side products that can form upon heating the reaction are minimized with shorter reaction times. For example, in the case where a PUFA is the labile compound, oxidation products that form upon heating are reduced. Thus the resulting product contains a high-quality PUFA which contains little or no oxidation products.
- In some embodiments, the first encapsulated product comprises the amino acid source and the reducing sugar source. In some embodiments, the first encapsulated product comprises the amino acid source and the second encapsulant comprises the reducing sugar source. In other embodiments, the first encapsulated product comprises the reducing sugar source and the second encapsulant comprises the amino acid source. In still other embodiments, the second encapsulant comprises the reducing sugar and the amino acid source. In other embodiments, the amino acid source and/or the reducing sugar source can be present in both the first encapsulated product and the second encapsulant.
- In another embodiment, the second encapsulant comprises an MRP. Accordingly, in one embodiment, the invention provides a product comprising a composition comprising a labile compound, a first encapsulant of the composition, a second encapsulant of the first encapsulant, wherein the second encapsulant further comprises a Maillard reaction product. In this embodiment, for example, the MRP can be produced separately and introduced into the second encapsulant prior to encapsulation of the first encapsulant. Alternatively, in embodiments in which one or both of the reducing sugar and amino acid source are in the second encapsulant, MRPs will be formed throughout the second encapsulant. As the second encapsulant is cooled and formed into a coating, as in a prilling process, the MRPs will be dispersed throughout the second encapsulant. In such embodiments, MRPs will occur, not just at the interface between the first and second encapsulants, but in the outer portions of the second encapsulant away from the first encapsulant. For example, the MRPs will occur in the outer 75%, 50% or 25% of the second encapsulant.
- The products of the present invention can be is characterized in general by parameters such as particle size and distribution, particle geometry, active contents and distribution, release mechanism, arid storage stability. In some embodiments in which the product is in a powder fonn, the product has a particle size of between about 10 μm and about 3000 μm, and in another embodiment between about 40 μm and 300 μm. Generally, the products are insoluble in cold to warm water, and in some embodiments, have a water solubility of less than about 0.1 mg/ml. The solubility of the product in a given environment will depend on the melting point of the second encapsulant. One skilled in the art can select an appropriate second encapsulant for the anticipated use and environment for the product.
- The products of the invention are generally physically stable. In some embodiments, the product is physically stable for at least about 30 days, at least about 60 days, at least about 90 days, at least about 120 days, at least about one year, at least about three years, or at least about five years. Physical stability refers to the ability of a product to maintain its physical appearance over time. For example, the structure of a product, with the first encapsulant of the composition and the second encapsulant of the first encapsulant, is substantially maintained without, for example, the composition migrating through the first encapsulant to the second encapsulant.
- In various embodiments, the products the invention are oxidatively stable. As used herein, oxidative stability refers to the lack of significant oxidation in the labile compound over a period of time. Oxidative stability of fats and oils can be determined by one skilled in the art. For example, peroxide values indicate the amount of peroxides present in the fat and are generally expressed in milli-equivalent oxygen per kg fat or oil. Additionally, anisidine values measure carbonyl (aldehydes and ketones) components which are formed during deterioration of oils. Anisidine values can be determined as described in IUPAC, Standard Methods for the Analysis of Oils, Fats and Derivatives, 6th Ed. (1979), Pergamon Press, Oxford, Method 2,504, page 143. The products of the invention, in some embodiments, have a peroxide value of less than about 2, or less than about 1. In other embodiments, products of the invention have an anisidine value of less than about 1. In some embodiments, the product is oxidatively stable for at least about 30 days, at least about 60 days, at least about 90 days, at least about 120 days, at least about one year, at least about three years, or at least about five years.
- In other embodiments of the invention, the products have desirable aromas or flavors. In some embodiments, a desirable aroma or flavor is due to the presence of Maillard reaction products. In other embodiments, a desirable aroma or flavor, or lack of an undesirable aroma or flavor, is imparted to the product by the physical and oxidative stability of the product. The presence of desirable aromas and flavors can be evaluated by one skilled in the art. For example, the room-odor characteristics of cooking oils can be reproducibly characterized by trained test panels in room-odor tests (Mounts, J. Am. Oil Chem. Soc. 56:659-663, 1979). A standardized technique for the sensory evaluation of edible vegetable oils is presented in AOCS' Recommended Practice Cg 2-83 for the Flavor Evaluation of Vegetable Oils (Methods and Standard Practices of the AOCS, 4th Edition (1989)). The technique encompasses standard sample preparation and presentation, as well as reference standards and method for scoring oils. Panelists can be asked to rank the products on a Hedonic scale. Such a scale can be a scale of 1-10 used for the overall odor and flavor in which 10 is assigned to “complete blandness”, and 1 to “strong obnoxiousness”. The higher score will indicate better product in terms of aroma and flavor. In some embodiments, products of the present invention will have a score of at least about 5, at least about 6, at least about 7, at least about 8, at least about 9 or about 10 in such a test. Such evaluations can be conducted at various time frames, such as upon production of the product, at least about 60 days after production, at least about 90 days after production, at least about 120 days after production, at least about one year after production, at least about three years after production, or at least about five years after production.
- The amount of labile compound in the products of the invention will vary depending on the type of compound, the encapsulation materials used, and the methods used for forming the product. In some embodiments, the product comprises labile compound in an amount of at least about 1 to 20 weight percent, in 1% increments and up to about 40 to 80 weight percent, in 1% increments, for example, between about 1 weight percent and about 80 weight percent, between about 5 weight percent and about 70 weight percent, between about 10 weight percent and about 60 weight percent, or between about 15 weight percent and about 50 weight percent.
- The present invention also provides methods for preparing the products described herein. Some of these methods have been described above.
- In one particular embodiment, the invention provides a method for preparing a product comprising encapsulating a first encapsulated product in the presence of an amino acid source and a reducing sugar to form a second encapsulated product. In the process of encapsulating a first encapsulated product, Maillard reaction products are formed. In this embodiment, the first encapsulated product comprises an encapsulant of a labile compound.
- In some embodiments, this method further includes handling the labile compound under conditions that reduce oxidative degradation prior to encapsulation. Such handling can include, for example, maintaining the product in an inert atmosphere, the addition of antioxidants to the labile compound, and so forth. In some embodiments, this method further comprises processing the second encapsulated product into a particulate form. In some embodiments, the particulate form can be selected from the group consisting of a bead, a chip, and a flake.
- In one embodiment, the first encapsulated product is formed by a method comprising emulsifying an aqueous dispersion of a polyunsaturated fatty acid, protein and reducing sugar to form an emulsion. This method further includes drying the emulsion to form the first encapsulated product.
- In some embodiments, encapsulating the first encapsulated product comprises contacting the first encapsulated product with a prilling material, spraying the mixture of the first encapsulated product with the prilling material into droplets, and cooling the droplets below the melting point of the prilling material to form the second encapsulated product. In some embodiments, the prilling material has a melting point in the range of about 32° C. to about 122° C. In other embodiments, the step of contacting the first encapsulated product with the prilling material is conducted at a temperature above about 85° C. In still other embodiments, the step of contacting the first encapsulated product with the prilling material is conducted for between about 1 minute and about 15 minutes. In some embodiments, the prilling material is hydrogenated vegetable oil, and the step of contacting the first encapsulated product with the prilling material is conducted for between about 1 minute and about 15 minutes, between 80° C. and 100° C.
- In some embodiments, the first encapsulated product comprises about 25 wt % to about 80 wt % labile compound; about 5 wt % to about 25 wt % of an amino acid source; and about 15 wt % to about 70 wt % of a reducing sugar.
- The products of the present invention can be incorporated into nutritional products (including food products, food supplements, feed products, feed supplements, and nutraceutical products), cosmetic products, pharmaceutical products, and industrial products. Products can be in the form of chewable tablets, quick dissolve tablets, effervescent tablets, reconstitutable powders, elixirs, liquids, solutions, suspensions, emulsions, tablets, multi-layer tablets, bi-layer tablets, capsules, soft gelatin capsules, hard gelatin capsules, caplets, lozenges, chewable lozenges, beads, powders, granules, particles, dispersible granules, dietary supplements, genetically engineered designer foods, herbal products, and processed foods.
- A nutritional product may be used directly as a food product, food supplement, feed product, feed supplement or as an ingredient in any of the foregoing. Food products can be liquid food products or solid food products. Liquid food products include, for example, infant formula, liquid meals, liquid eggs, multivitamin syrups, meal replacers, medicinal foods, soups and syrups, and beverages. As used herein a beverage is any one of various liquids for drinking. Beverages include, for example, energy drinks, fruit juices, milk, and milk products. Solid food products include, for example, baby food, yogurt, cheese, cereal, powdered mixes, baked goods, including, for example, such items as cakes, cheesecakes, pies, cupcakes, cookies, bars, breads, rolls, biscuits, muffins, pastries, scones, and croutons, food bars including energy bars, and processed meats. Also included are doughs, batters, ice creams; frozen desserts; frozen yogurts; waffle mixes; salad dressings; and replacement egg mixes, baked goods such as cookies, crackers, sweet goods, snack cakes, pies, granola/snack bars, and toaster pastries; salted snacks such as potato chips, corn chips, tortilla chips, extruded snacks, popcorn, pretzels, potato crisps, and nuts; specialty snacks such as dips, dried fruit snacks, meat snacks, pork rinds, health food bars and rice/corn cakes; and confectionary snacks such as candy. In some embodiments, particularly including some solid food products, the product can be processed into a particulate form. For example, the particulate form can be selected from the group consisting of a bead, a chip, and a flake.
- Feed or feed supplements can be prepared for any companion animal or pet or for any animal whose meat or products are consumed by humans. The term “animal” means any organism belonging to the kingdom Animalia and includes, without limitation, any animal from which poultry meat, seafood, beef, pork or lamb is derived. Seafood is derived from, without limitation, fish, shrimp and shellfish. Animal product includes any product other than meat derived from such animals, including, without limitation, eggs, milk or other products. When fed to such animals, nutrients such as LC PUFAs can be incorporated into the flesh, milk, eggs or other products of such animals to increase their content of these nutrients.
- A cosmetic product is a product that is applied to the skin and can function either to improve the appearance of the skin or to provide some dermatological benefit to the skin.
- An industrial product is a product such as a raw material for manufacturing paints, wood products, textiles, adhesives, sealants, lubricants, leather, rope, paper pulp, plastics, fuels, oil, rubber working fluids, or metal working fluids.
- Additional objects, advantages, and novel features of this invention will become apparent to those skilled in the art upon examination of the following examples thereof, which are not intended to be limiting.
- This example illustrates the production of a product of the present invention in which the composition comprising a labile compound is an algal oil and the first encapsulant is formed by spray drying. The second encapsulant is a prill coating of hydrogenated canola wax.
- Spray dried particles of algal oil in a sugar-protein matrix, prepared in accordance with the process generally described in EP 1 616 486, entitled Powdered Compositions Containing an Edible Oil and Their Use in Food Products, which is incorporated herein by reference, with a mean size of 78 μm were prilled in hydrogenated canola wax (Stable Flake—CN, Cargill). This material was prilled at a concentration of 33% (one-third by weight spray dried particles with two-thirds by weight canola oil) with good results. The resulting product had a mean particle size of 157 microns.
- This example illustrates the production of a product of the present invention in which first encapsulant of the composition comprising the labile compound is a biomass hydrolysate. The second encapsulant is a prill coating of hydrogenated canola wax.
- Two pounds of dried biomass hydrolysate powder containing 22% DHA were added to molten, hydrogenated canola fat (Stable Flake—CN, Cargill) at 100° C. to make a molten solution containing 25% biomass hydrolysate (5.5% DHA) at 80° C. The biomass hydrolyzate powder was produced in accordance with the process generally described in U.S. patent application Ser. No. 11/433,752, filed on May 12, 2006, entitled Biomass Hydrolysate and Uses and Production Thereof, which is incorporated herein by reference.
- The resultant solution was atomized using compressed air at 154° C. and 45 psi into a prill tower using ambient air as the cooling air. The powder was collected and analyzed for particle size, solubility and sensory profile. The particle size of the original hydrolysate power was 70.5 micron. The average particle size of the prills was 82.9 micron. The powder was found to be mostly water insoluble with improved, pleasant aroma and acceptable sensory profile.
- This example illustrates the stability of the products of the invention. Two samples were utilized. The product of the present invention is one in which composition comprising a labile compound is an algal oil and the first encapsulant is formed by reacting a solution comprising a protein, soy protein isolate, and a reducing sugar at a starting pH of 10 to achieve a degree of protein hydrolysis of between about 1% and about 15%, and combining the reacted solution with the algal oil, such that the reacted solution forms an encapsulant on the algal oil, and spray drying resulting mixture. This method is described in detail in U.S. provisional patent application Ser. No. 60/945,040, filed Jun. 19, 2007, which is herein incorporated by reference in its entirety. The second encapsulant is a prill coating of hydrogenated soy fat. For comparison purposes, the algal oil with a first encapsulant and no second encapsulant was used.
- Product samples were stored at 40° C. to accelerate oxidative degradation. They were evaluated weekly by trained sensory panelists in order to detect oxidation products. Additionally, the samples were tested weekly by Gas Chromatography/Mass Spectrometry for static headspace of propanal and hexanal. Results are expressed as induction period. Induction period for the sample was defined as the time when an average sensory score of 3.0 or greater first appeared (based on a 5 point scale). Head space induction periods are defined as the time there is a sharp increase (inflection point) in the concentration of volatiles hexanal and propanal. Results are shown in
FIG. 1 . Sensory analysis indicates prilling of core material results in nearly an 8-fold increase in induction period (3 wks vs. 23 wks). Additionally, relative stability as determined by GC/MS indicates a 9-fold increase in shelf life (2 wks vs. 19 wks). Results such as these clearly underscore the additional stability imparted as singly encapsulated product is prilled. - The foregoing description of the present invention has been presented for purposes of illustration and description. Furthermore, the description is not intended to limit the invention to the form disclosed herein. Consequently, variations and modifications commensurate with the above teachings, and the skill or knowledge of the relevant art, are within the scope of the present invention. The embodiment described hereinabove is further intended to explain the best mode known for practicing the invention and to enable others skilled in the art to utilize the invention in such, or other, embodiments and with various modifications required by the particular applications or uses of the present invention. It is intended that the appended claims be construed to include alternative embodiments to the extent permitted by the prior art.
Claims (49)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/767,366 US8221809B2 (en) | 2006-06-22 | 2007-06-22 | Encapsulated labile compound compositions and methods of making the same |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80559006P | 2006-06-22 | 2006-06-22 | |
US94504007P | 2007-06-19 | 2007-06-19 | |
US11/767,366 US8221809B2 (en) | 2006-06-22 | 2007-06-22 | Encapsulated labile compound compositions and methods of making the same |
Publications (2)
Publication Number | Publication Date |
---|---|
US20080026108A1 true US20080026108A1 (en) | 2008-01-31 |
US8221809B2 US8221809B2 (en) | 2012-07-17 |
Family
ID=38986632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/767,366 Active 2029-02-18 US8221809B2 (en) | 2006-06-22 | 2007-06-22 | Encapsulated labile compound compositions and methods of making the same |
Country Status (1)
Country | Link |
---|---|
US (1) | US8221809B2 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090004233A1 (en) * | 2007-06-19 | 2009-01-01 | Connolly Brian J | Microencapsulating compositions, methods of making, methods of using and products thereof |
US20090110773A1 (en) * | 2007-10-24 | 2009-04-30 | Dwivedi Basant K | Fruit Snack with Probiotics and Method of Manufacturing a Fruit Snack with Probiotics |
US20090196949A1 (en) * | 2008-02-05 | 2009-08-06 | Lignotech Usa, Inc. | Ruminant feed |
WO2010130856A1 (en) * | 2009-05-11 | 2010-11-18 | Maria Pilar Mateo Herrero | Microencapsulated composition based on saponified olea europaea, use thereof and production method of same |
US20110020519A1 (en) * | 2008-01-04 | 2011-01-27 | Aveka, Inc. | Encapsulation of oxidatively unstable compounds |
US20110052680A1 (en) * | 2008-01-04 | 2011-03-03 | AVERA, Inc. | Encapsulation of oxidatively unstable compounds |
WO2011146186A2 (en) * | 2010-05-17 | 2011-11-24 | Georgia-Pacific Chemicals Llc | Proppants for use in hydraulic fracturing of subterranean formations |
US20120058232A1 (en) * | 2010-02-10 | 2012-03-08 | Gaofeng Liu | Method for the preparation of diacetyl tartaric acid esters of mono-and di-glycerides |
US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
US20130316004A1 (en) * | 2011-02-07 | 2013-11-28 | Life Technologies Corporation | Compositions and methods for stabilizing susceptible compounds |
WO2014169315A1 (en) * | 2013-04-19 | 2014-10-23 | Commonwealth Scientific And Industrial Research Organisation | Encapsulation method |
US20150296821A1 (en) * | 2012-04-12 | 2015-10-22 | Compagnie Gervais Danone | Fermented Dairy Product Comprising Microcapsules And Process For Preparing The Same |
CN106262723A (en) * | 2016-08-18 | 2017-01-04 | 江苏华桑食品科技有限公司 | A kind of preparation method of too prince wife beans |
CN109833297A (en) * | 2017-11-27 | 2019-06-04 | 张正风 | A kind of micro- rouge body composition |
CN110179093A (en) * | 2019-06-27 | 2019-08-30 | 北京工商大学 | A kind of universal enzymolysis liquid and application thereof for Maillard reaction |
CN110236201A (en) * | 2019-06-04 | 2019-09-17 | 宁波希诺亚海洋生物科技有限公司 | Preparation method applied to the ferric pyrophosphate in infant food |
CN112004935A (en) * | 2018-03-30 | 2020-11-27 | 帝斯曼知识产权资产管理有限公司 | Method for obtaining microbial oils and method for reducing emulsions by maintaining low carbohydrate concentrations |
WO2021165516A1 (en) | 2020-02-19 | 2021-08-26 | Anabio Technologies Limited | Coated microcapsules and methods for the production thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140199439A1 (en) * | 2013-01-14 | 2014-07-17 | Sunny Delight Beverages Company | Coated calcium particulates for use in beverage products |
AU2016278194A1 (en) | 2015-06-19 | 2018-02-08 | Nexentia S.A.S. | Method for producing colloidosome microcapsules |
CN107242350B (en) * | 2016-07-05 | 2021-02-09 | 南京农业大学 | Selenium-rich lactobacillus preparation capable of degrading oxalic acid and preparation method and application thereof |
US11849747B1 (en) | 2019-06-24 | 2023-12-26 | PBM Nutritionals, LLC | Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof |
Citations (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3655864A (en) * | 1970-09-21 | 1972-04-11 | Smith Kline French Lab | Glyceryl tristerate and higher fatty acid mixture for improving digestive absorption |
US3804776A (en) * | 1970-12-14 | 1974-04-16 | Fuji Photo Film Co Ltd | Method of producing oil and fat encapsulated amino acids |
US3819838A (en) * | 1970-08-04 | 1974-06-25 | Bush Boake Allen Ltd | Encapsulated flavoring composition |
US4217370A (en) * | 1977-08-25 | 1980-08-12 | Blue Wing Corporation | Lipid-containing feed supplements and foodstuffs |
US4332790A (en) * | 1978-12-05 | 1982-06-01 | Societe D'assistance Technique Pour Produits Nestle S.A. | Microcapsule containing a microorganism and a process for its production |
US4533557A (en) * | 1982-04-02 | 1985-08-06 | Nippon Soda Co. Ltd. | Feed additives for ruminants |
US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4678710A (en) * | 1984-10-22 | 1987-07-07 | Showa Denko K. K. | Coated particulate materials and method for manufacture thereof |
US4895725A (en) * | 1987-08-24 | 1990-01-23 | Clinical Technologies Associates, Inc. | Microencapsulation of fish oil |
US4957748A (en) * | 1987-03-23 | 1990-09-18 | The Board Of Regents Of The University Of Nebraska | Ruminant feed, method of making and method of using |
US5015483A (en) * | 1989-02-09 | 1991-05-14 | Nabisco Brands, Inc. | Liposome composition for the stabilization of oxidizable substances |
US5106639A (en) * | 1990-02-10 | 1992-04-21 | Korea Food Research Institute | Fatty fodder additives for use in producing meat with a high content of omega-3-fatty acids and low content of cholesterol, and process for preparing same |
US5143737A (en) * | 1989-10-13 | 1992-09-01 | The Regents Of The University Of California | Method to produce unsaturated milk fat and meat from ruminant animals |
US5153177A (en) * | 1991-01-10 | 1992-10-06 | Basf Corporation | Process for incorporating a material in a crosslinked gelatin, and product therefrom |
US5190775A (en) * | 1991-05-29 | 1993-03-02 | Balchem Corporation | Encapsulated bioactive substances |
US5206041A (en) * | 1988-11-16 | 1993-04-27 | Cbp Resources, Inc. | Ruminant animal feed supplement |
US5213810A (en) * | 1990-03-30 | 1993-05-25 | American Cyanamid Company | Stable compositions for parenteral administration and method of making same |
US5356636A (en) * | 1991-12-14 | 1994-10-18 | Basf Aktiengesellschaft | Stable vitamin and/or carotenoid products in powder form, and the preparation thereof |
US5496571A (en) * | 1992-12-30 | 1996-03-05 | Morgan Manufacturing Co., Inc. | Method for increasing the production of milk in ruminants |
US5698244A (en) * | 1988-09-07 | 1997-12-16 | Omegatech Inc. | Method for raising animals having high concentrations of omega-3 highly unsaturated fatty acids |
US5756143A (en) * | 1995-04-28 | 1998-05-26 | Loders-Croklaan B.V. | Triglycerides, rich in polyunsaturated fatty acids |
US5789001A (en) * | 1995-06-09 | 1998-08-04 | University Of Nebraska | Ruminant feed and method for making |
US5874470A (en) * | 1987-10-09 | 1999-02-23 | B. Braun Melsungen Ag | Isotonic fat emulsion containing omega-3-fatty acids and use thereof |
US5908654A (en) * | 1995-04-28 | 1999-06-01 | Loders-Croklaan B.V. | Triglycerides rich in polyunsaturated fatty acids |
US5985348A (en) * | 1995-06-07 | 1999-11-16 | Omegatech, Inc. | Milk products having high concentrations of omega-3 highly unsaturated fatty acids |
US6083520A (en) * | 1994-05-19 | 2000-07-04 | Ewos Aktiebolag | Bioactive feed |
US6245366B1 (en) * | 1996-10-25 | 2001-06-12 | Mccormick & Company, Inc. | Fat-coated encapsulation compositions and method for preparing the same |
US6248909B1 (en) * | 1998-06-19 | 2001-06-19 | Suntory Limited | Triglyceride and composition comprising the same |
US6258964B1 (en) * | 1997-06-11 | 2001-07-10 | Idemitsu Petrochemical Co., Ltd. | Method for extracting fat-soluble components from microbial cells |
US6444227B1 (en) * | 1999-08-05 | 2002-09-03 | Roche Vitamins Inc. | Process for preparing fat soluble beadlets |
US6444242B1 (en) * | 1992-07-06 | 2002-09-03 | Danochemo A/S | Microencapsulated oil or fat product |
US20030072787A1 (en) * | 2000-06-01 | 2003-04-17 | Wilson Mark E. | Animal food and method |
US6599556B2 (en) * | 2000-11-21 | 2003-07-29 | Cargill, Inc. | Protein supplemented confectionery compositions |
US20030185960A1 (en) * | 2000-04-04 | 2003-10-02 | Augustin Mary Ann | Encapsulation of food ingredients |
US20030193102A1 (en) * | 2002-04-11 | 2003-10-16 | Nianxi Yan | Encapsulated agglomeration of microcapsules and method for the preparation thereof |
US20030211221A1 (en) * | 2000-06-26 | 2003-11-13 | Abril Jesus R. | Methods of incorporating polyunsaturated fatty acids in milk |
US6770104B2 (en) * | 2001-05-11 | 2004-08-03 | Cargill, Incorporated | Triacylglycerol based candle wax |
US20040191390A1 (en) * | 2003-03-31 | 2004-09-30 | Lee John H. | Encapsulated oil and fat products with free fatty acids |
US20050067726A1 (en) * | 2002-11-04 | 2005-03-31 | Nianxi Yan | Microcapsules having multiple shells and method for the preparation thereof |
US20050233002A1 (en) * | 2004-04-15 | 2005-10-20 | Trubiano Paolo C | Encapsulation of oxygen sensitive agents |
US20050238788A1 (en) * | 2004-04-22 | 2005-10-27 | Wynn Starr Flavors, Inc. | Shelf-stable flavored oil encapsulated salt |
US20050281926A1 (en) * | 2004-06-10 | 2005-12-22 | Kellogg Company | Topical application of marine oils to food |
US6991823B2 (en) * | 2000-03-31 | 2006-01-31 | Commonwealth Scientific & Industrial Research Organization Centre | Nutritional mineral fortification of milk |
US7001610B2 (en) * | 2001-04-23 | 2006-02-21 | Omeganutrel Inc. | Food supplement and use thereof for elevating levels of essential fatty acids in livestock and products therefrom |
US20060159805A1 (en) * | 2003-07-15 | 2006-07-20 | Elger Funda | Powderous formulations of fat-soluble active ingredients |
US20060286205A1 (en) * | 2005-05-12 | 2006-12-21 | Martek Biosciences Corporation | Biomass hydrolysate and uses and production thereof |
US20080096964A1 (en) * | 2006-08-25 | 2008-04-24 | Martek Biosciences Corporation | Food Fortification with Polyunsaturated Fatty Acids |
US20090004233A1 (en) * | 2007-06-19 | 2009-01-01 | Connolly Brian J | Microencapsulating compositions, methods of making, methods of using and products thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1217365A (en) | 1967-02-23 | 1970-12-31 | Labatt Ltd John | Controlled release feed additives for ruminants |
CA1301775C (en) | 1986-06-04 | 1992-05-26 | Karel Petrus Agnes Maria Van Putte | Fractionation of fat blends |
JPH0732872B2 (en) | 1986-07-16 | 1995-04-12 | 明治乳業株式会社 | Method for producing microcapsules containing highly unsaturated fatty acids and oils |
DE69002658T2 (en) | 1989-02-09 | 1993-11-25 | Nestle Sa | Fat-dry emulsion and process for its preparation. |
IT1229194B (en) | 1989-03-03 | 1991-07-25 | Ind Italiana Integratori Trei | CONTROLLED RELEASE PROTECTIVE DIES FOR ZOOTECHNICAL AND VETERINARY USE. |
WO1991005482A1 (en) | 1989-10-13 | 1991-05-02 | The Regents Of The University Of California | Method to produce unsaturated milk fat and meat from ruminant animals |
BR9205526A (en) | 1991-01-24 | 1994-04-19 | Martek Corp Sociedade Norte Am | Mixtures of microbial oils and their uses |
ATE207362T1 (en) | 1993-05-28 | 2001-11-15 | Ascor Chimici Srl | VETERINARY COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF INFECTIONS AND DISEASES |
IES62578B2 (en) | 1993-08-31 | 1995-02-08 | Charleville Res | "An edible fat blend containing fish oil" |
JPH08336360A (en) | 1995-03-17 | 1996-12-24 | Kanagawa Kagaku Kenkyusho:Kk | Feed composition for ruminant and feeding using the same |
EP0831805A1 (en) | 1995-06-07 | 1998-04-01 | Martek Biosciences Corporation | Methods for controlling highly unsaturated fatty acid content in various tissues |
JP2000501131A (en) | 1995-11-24 | 2000-02-02 | ロダース・クロックラーン・ビー・ブイ | Compositions based on fish oil |
EP1006806B1 (en) | 1996-04-11 | 2006-09-13 | Loders Croklaan B.V. | Free flowing fat compositions |
IL126741A0 (en) | 1998-10-25 | 1999-08-17 | Yam Daniel | Solidification of fluid oils and their use |
SE523211C2 (en) | 2000-04-26 | 2004-04-06 | Skaanemejerier Ekonomisk Foere | Lipid composition comprising a protective oil and a polyunsaturated fatty acid, emulsion containing such a composition and process for preparing the emulsion |
US8871266B2 (en) | 2003-10-01 | 2014-10-28 | Commonwealth Scientific & Industrial Research Organisation | Probiotic storage and delivery |
ES2373937T3 (en) | 2003-11-21 | 2012-02-10 | Commonwealth Scientific And Industrial Research Organisation | GASTRO-INTESTINAL ADMINISTRATION SYSTEMS. |
ES2235642B2 (en) | 2003-12-18 | 2006-03-01 | Gat Formulation Gmbh | CONTINUOUS MULTI-MICROENCAPSULATION PROCESS FOR THE IMPROVEMENT OF STABILITY AND STORAGE OF BIOLOGICALLY ACTIVE INGREDIENTS. |
CA2559473C (en) | 2004-03-18 | 2015-07-21 | Dsm Ip Assets B.V. | Extrusion-stable poly-unsaturated fatty-acid compositions for food products |
JP5001834B2 (en) | 2004-04-28 | 2012-08-15 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション | Starch processing method |
EP1616486A1 (en) | 2004-07-13 | 2006-01-18 | Friesland Brands B.V. | Powdered compositions containing an edible oil and their use in food products |
SE528747C2 (en) | 2005-06-23 | 2007-02-06 | Forskarpatent I Syd Ab | Casein complex, tasty product containing the same and process for its preparation |
-
2007
- 2007-06-22 US US11/767,366 patent/US8221809B2/en active Active
Patent Citations (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3819838A (en) * | 1970-08-04 | 1974-06-25 | Bush Boake Allen Ltd | Encapsulated flavoring composition |
US3655864A (en) * | 1970-09-21 | 1972-04-11 | Smith Kline French Lab | Glyceryl tristerate and higher fatty acid mixture for improving digestive absorption |
US3804776A (en) * | 1970-12-14 | 1974-04-16 | Fuji Photo Film Co Ltd | Method of producing oil and fat encapsulated amino acids |
US4217370A (en) * | 1977-08-25 | 1980-08-12 | Blue Wing Corporation | Lipid-containing feed supplements and foodstuffs |
US4332790A (en) * | 1978-12-05 | 1982-06-01 | Societe D'assistance Technique Pour Produits Nestle S.A. | Microcapsule containing a microorganism and a process for its production |
US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4533557A (en) * | 1982-04-02 | 1985-08-06 | Nippon Soda Co. Ltd. | Feed additives for ruminants |
US4678710A (en) * | 1984-10-22 | 1987-07-07 | Showa Denko K. K. | Coated particulate materials and method for manufacture thereof |
US4957748A (en) * | 1987-03-23 | 1990-09-18 | The Board Of Regents Of The University Of Nebraska | Ruminant feed, method of making and method of using |
US4895725A (en) * | 1987-08-24 | 1990-01-23 | Clinical Technologies Associates, Inc. | Microencapsulation of fish oil |
US5874470A (en) * | 1987-10-09 | 1999-02-23 | B. Braun Melsungen Ag | Isotonic fat emulsion containing omega-3-fatty acids and use thereof |
US5698244A (en) * | 1988-09-07 | 1997-12-16 | Omegatech Inc. | Method for raising animals having high concentrations of omega-3 highly unsaturated fatty acids |
US5206041A (en) * | 1988-11-16 | 1993-04-27 | Cbp Resources, Inc. | Ruminant animal feed supplement |
US5015483A (en) * | 1989-02-09 | 1991-05-14 | Nabisco Brands, Inc. | Liposome composition for the stabilization of oxidizable substances |
US5143737A (en) * | 1989-10-13 | 1992-09-01 | The Regents Of The University Of California | Method to produce unsaturated milk fat and meat from ruminant animals |
US5106639A (en) * | 1990-02-10 | 1992-04-21 | Korea Food Research Institute | Fatty fodder additives for use in producing meat with a high content of omega-3-fatty acids and low content of cholesterol, and process for preparing same |
US5213810A (en) * | 1990-03-30 | 1993-05-25 | American Cyanamid Company | Stable compositions for parenteral administration and method of making same |
US5153177A (en) * | 1991-01-10 | 1992-10-06 | Basf Corporation | Process for incorporating a material in a crosslinked gelatin, and product therefrom |
US5190775A (en) * | 1991-05-29 | 1993-03-02 | Balchem Corporation | Encapsulated bioactive substances |
US6013286A (en) * | 1991-05-29 | 2000-01-11 | Balchem Corporation | Encapsulated bioactive substances |
US5356636A (en) * | 1991-12-14 | 1994-10-18 | Basf Aktiengesellschaft | Stable vitamin and/or carotenoid products in powder form, and the preparation thereof |
US6444242B1 (en) * | 1992-07-06 | 2002-09-03 | Danochemo A/S | Microencapsulated oil or fat product |
US5496571A (en) * | 1992-12-30 | 1996-03-05 | Morgan Manufacturing Co., Inc. | Method for increasing the production of milk in ruminants |
US6083520A (en) * | 1994-05-19 | 2000-07-04 | Ewos Aktiebolag | Bioactive feed |
US5908654A (en) * | 1995-04-28 | 1999-06-01 | Loders-Croklaan B.V. | Triglycerides rich in polyunsaturated fatty acids |
US5756143A (en) * | 1995-04-28 | 1998-05-26 | Loders-Croklaan B.V. | Triglycerides, rich in polyunsaturated fatty acids |
US5985348A (en) * | 1995-06-07 | 1999-11-16 | Omegatech, Inc. | Milk products having high concentrations of omega-3 highly unsaturated fatty acids |
US5789001A (en) * | 1995-06-09 | 1998-08-04 | University Of Nebraska | Ruminant feed and method for making |
US6245366B1 (en) * | 1996-10-25 | 2001-06-12 | Mccormick & Company, Inc. | Fat-coated encapsulation compositions and method for preparing the same |
US6258964B1 (en) * | 1997-06-11 | 2001-07-10 | Idemitsu Petrochemical Co., Ltd. | Method for extracting fat-soluble components from microbial cells |
US6248909B1 (en) * | 1998-06-19 | 2001-06-19 | Suntory Limited | Triglyceride and composition comprising the same |
US6444227B1 (en) * | 1999-08-05 | 2002-09-03 | Roche Vitamins Inc. | Process for preparing fat soluble beadlets |
US6991823B2 (en) * | 2000-03-31 | 2006-01-31 | Commonwealth Scientific & Industrial Research Organization Centre | Nutritional mineral fortification of milk |
US20030185960A1 (en) * | 2000-04-04 | 2003-10-02 | Augustin Mary Ann | Encapsulation of food ingredients |
US20030072787A1 (en) * | 2000-06-01 | 2003-04-17 | Wilson Mark E. | Animal food and method |
US20080020086A1 (en) * | 2000-06-26 | 2008-01-24 | Martek Biosciences Corporation | Methods of Incorporating Polyunsaturated Fatty Acids in Milk |
US20030211221A1 (en) * | 2000-06-26 | 2003-11-13 | Abril Jesus R. | Methods of incorporating polyunsaturated fatty acids in milk |
US6599556B2 (en) * | 2000-11-21 | 2003-07-29 | Cargill, Inc. | Protein supplemented confectionery compositions |
US7001610B2 (en) * | 2001-04-23 | 2006-02-21 | Omeganutrel Inc. | Food supplement and use thereof for elevating levels of essential fatty acids in livestock and products therefrom |
US6770104B2 (en) * | 2001-05-11 | 2004-08-03 | Cargill, Incorporated | Triacylglycerol based candle wax |
US6974592B2 (en) * | 2002-04-11 | 2005-12-13 | Ocean Nutrition Canada Limited | Encapsulated agglomeration of microcapsules and method for the preparation thereof |
US20050019416A1 (en) * | 2002-04-11 | 2005-01-27 | Ocean Nutrition Canada Ltd. | Encapsulated agglomeration of microcapsules and method for the preparation thereof |
US20030193102A1 (en) * | 2002-04-11 | 2003-10-16 | Nianxi Yan | Encapsulated agglomeration of microcapsules and method for the preparation thereof |
US20050067726A1 (en) * | 2002-11-04 | 2005-03-31 | Nianxi Yan | Microcapsules having multiple shells and method for the preparation thereof |
US20040191390A1 (en) * | 2003-03-31 | 2004-09-30 | Lee John H. | Encapsulated oil and fat products with free fatty acids |
US20060159805A1 (en) * | 2003-07-15 | 2006-07-20 | Elger Funda | Powderous formulations of fat-soluble active ingredients |
US20050233002A1 (en) * | 2004-04-15 | 2005-10-20 | Trubiano Paolo C | Encapsulation of oxygen sensitive agents |
US20050238788A1 (en) * | 2004-04-22 | 2005-10-27 | Wynn Starr Flavors, Inc. | Shelf-stable flavored oil encapsulated salt |
US20050281926A1 (en) * | 2004-06-10 | 2005-12-22 | Kellogg Company | Topical application of marine oils to food |
US20060286205A1 (en) * | 2005-05-12 | 2006-12-21 | Martek Biosciences Corporation | Biomass hydrolysate and uses and production thereof |
US20080096964A1 (en) * | 2006-08-25 | 2008-04-24 | Martek Biosciences Corporation | Food Fortification with Polyunsaturated Fatty Acids |
US20090004233A1 (en) * | 2007-06-19 | 2009-01-01 | Connolly Brian J | Microencapsulating compositions, methods of making, methods of using and products thereof |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090004233A1 (en) * | 2007-06-19 | 2009-01-01 | Connolly Brian J | Microencapsulating compositions, methods of making, methods of using and products thereof |
US20090110773A1 (en) * | 2007-10-24 | 2009-04-30 | Dwivedi Basant K | Fruit Snack with Probiotics and Method of Manufacturing a Fruit Snack with Probiotics |
US11317640B2 (en) | 2007-10-24 | 2022-05-03 | Promotion In Motion, Inc | Fruit snack with probiotics and method of manufacturing a fruit snack with probiotics |
US10602754B2 (en) | 2007-10-24 | 2020-03-31 | The Promotion In Motion Companies, Inc. | Fruit snack with probiotics and method of manufacturing a fruit snack with probiotics |
US9750267B2 (en) | 2007-10-24 | 2017-09-05 | The Promotion In Motion Companies, Inc. | Fruit snack with probiotics and method of manufacturing a fruit snack with probiotics |
US8741337B2 (en) | 2008-01-04 | 2014-06-03 | Aveka, Inc. | Encapsulation of oxidatively unstable compounds |
US20110020519A1 (en) * | 2008-01-04 | 2011-01-27 | Aveka, Inc. | Encapsulation of oxidatively unstable compounds |
US20110052680A1 (en) * | 2008-01-04 | 2011-03-03 | AVERA, Inc. | Encapsulation of oxidatively unstable compounds |
US20110059164A1 (en) * | 2008-01-04 | 2011-03-10 | Aveka, Inc. | Encapsulation of oxidatively unstable compounds |
US20090196949A1 (en) * | 2008-02-05 | 2009-08-06 | Lignotech Usa, Inc. | Ruminant feed |
WO2009100066A3 (en) * | 2008-02-05 | 2009-10-22 | Lignotech Usa, Inc. | Ruminant feed |
WO2009100066A2 (en) * | 2008-02-05 | 2009-08-13 | Lignotech Usa, Inc. | Ruminant feed |
WO2010130856A1 (en) * | 2009-05-11 | 2010-11-18 | Maria Pilar Mateo Herrero | Microencapsulated composition based on saponified olea europaea, use thereof and production method of same |
ES2350075A1 (en) * | 2009-05-11 | 2011-01-18 | Maria Pilar Mateo Herrero | Microencapsulated composition based on saponified olea europaea, use thereof and production method of same |
US20120058232A1 (en) * | 2010-02-10 | 2012-03-08 | Gaofeng Liu | Method for the preparation of diacetyl tartaric acid esters of mono-and di-glycerides |
CN102947413A (en) * | 2010-05-17 | 2013-02-27 | 佐治亚-太平洋化工品有限公司 | Proppants for use in hydraulic fracturing of subterranean formations |
US9777211B2 (en) | 2010-05-17 | 2017-10-03 | Georgia-Pacific Chemicals Llc | Proppants for use in hydraulic fracturing of subterranean formations |
US9045678B2 (en) | 2010-05-17 | 2015-06-02 | Georgia-Pacific Chemicals Llc | Proppants for use in hydraulic fracturing of subterranean formations |
WO2011146186A3 (en) * | 2010-05-17 | 2012-02-02 | Georgia-Pacific Chemicals Llc | Proppants for use in hydraulic fracturing of subterranean formations |
US10266758B2 (en) | 2010-05-17 | 2019-04-23 | Georgia-Pacific Chemicals Llc | Proppants for use in hydraulic fracturing of subterranean formations |
WO2011146186A2 (en) * | 2010-05-17 | 2011-11-24 | Georgia-Pacific Chemicals Llc | Proppants for use in hydraulic fracturing of subterranean formations |
US20210269767A1 (en) * | 2011-02-07 | 2021-09-02 | Life Technologies Corporation | Compositions and methods for stabilizing susceptible compounds |
US20130316004A1 (en) * | 2011-02-07 | 2013-11-28 | Life Technologies Corporation | Compositions and methods for stabilizing susceptible compounds |
US11028361B2 (en) | 2011-02-07 | 2021-06-08 | Life Technologies Corporation | Compositions and methods for stabilizing susceptible compounds |
US10669522B2 (en) * | 2011-02-07 | 2020-06-02 | Life Technologies Corporation | Compositions and methods for stabilizing susceptible compounds |
US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
US8545896B2 (en) | 2011-09-29 | 2013-10-01 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
US20150296821A1 (en) * | 2012-04-12 | 2015-10-22 | Compagnie Gervais Danone | Fermented Dairy Product Comprising Microcapsules And Process For Preparing The Same |
CN105142416A (en) * | 2013-04-19 | 2015-12-09 | 联邦科学和工业研究组织 | Encapsulation method |
US10785991B2 (en) | 2013-04-19 | 2020-09-29 | Commonwealth Scientific And Industrial Research Organisation | Encapsulation method |
WO2014169315A1 (en) * | 2013-04-19 | 2014-10-23 | Commonwealth Scientific And Industrial Research Organisation | Encapsulation method |
CN106262723A (en) * | 2016-08-18 | 2017-01-04 | 江苏华桑食品科技有限公司 | A kind of preparation method of too prince wife beans |
CN109833297A (en) * | 2017-11-27 | 2019-06-04 | 张正风 | A kind of micro- rouge body composition |
CN109833297B (en) * | 2017-11-27 | 2021-10-29 | 张正风 | Micro-lipid composition |
CN112004935A (en) * | 2018-03-30 | 2020-11-27 | 帝斯曼知识产权资产管理有限公司 | Method for obtaining microbial oils and method for reducing emulsions by maintaining low carbohydrate concentrations |
CN110236201A (en) * | 2019-06-04 | 2019-09-17 | 宁波希诺亚海洋生物科技有限公司 | Preparation method applied to the ferric pyrophosphate in infant food |
CN110179093A (en) * | 2019-06-27 | 2019-08-30 | 北京工商大学 | A kind of universal enzymolysis liquid and application thereof for Maillard reaction |
WO2021165516A1 (en) | 2020-02-19 | 2021-08-26 | Anabio Technologies Limited | Coated microcapsules and methods for the production thereof |
Also Published As
Publication number | Publication date |
---|---|
US8221809B2 (en) | 2012-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8221809B2 (en) | Encapsulated labile compound compositions and methods of making the same | |
CA2689590C (en) | Microencapsulating compositions, methods of making, methods of using and products thereof | |
CA2655044C (en) | Encapsulated labile compound compositions and methods of making the same | |
US20080096964A1 (en) | Food Fortification with Polyunsaturated Fatty Acids | |
EP2124905B1 (en) | Microcapsules including pea protein | |
US8048652B2 (en) | Biomass hydrolysate and uses and production thereof | |
WO2005115341A2 (en) | Microparticles for oral delivery | |
CA2855909A1 (en) | Oil body extraction and uses | |
US20080026109A1 (en) | Sweetened Oil Compositions and Methods of Making | |
TWI494135B (en) | Encapsulated labile compound compositions and methods of making the same | |
Jeyakumari et al. | Microencapsulation of Bioactive Food Ingredients: Methods, Applications, and Controlled Release Mechanism—a Review | |
Jeykumari et al. | Encapsulation of bioactive ingredients: Application and challenges |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AVEKA, INC., MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HENDRICKSON, WILLIAM A.;REEL/FRAME:019891/0423 Effective date: 20070918 Owner name: MARTEK BIOSCIENCES CORPORATION, MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AVEKA, INC.;REEL/FRAME:019891/0426 Effective date: 20070918 Owner name: MARTEK BIOSCIENCES CORPORATION, MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CONNOLLY, BRIAN J.;SUBRAMANIAN, SRINIVASAN;REEL/FRAME:019891/0450;SIGNING DATES FROM 20070730 TO 20070921 Owner name: MARTEK BIOSCIENCES CORPORATION, MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CONNOLLY, BRIAN J.;SUBRAMANIAN, SRINIVASAN;SIGNING DATES FROM 20070730 TO 20070921;REEL/FRAME:019891/0450 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: DSM IP ASSETS B.V., NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MARTEK BIOSCIENCES CORPORATION;REEL/FRAME:028698/0935 Effective date: 20120625 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |